<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria - Martí‐Carvajal, AJ - 2014 | Cochrane Library</title> <meta content="Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria - Martí‐Carvajal, AJ - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010340.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria - Martí‐Carvajal, AJ - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010340.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010340.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria" name="citation_title"/> <meta content="Arturo J Martí‐Carvajal" name="citation_author"/> <meta content="Iberoamerican Cochrane Network" name="citation_author_institution"/> <meta content="arturo.marti.carvajal@gmail.com" name="citation_author_email"/> <meta content="Vidhu Anand" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Andrés Felipe Cardona" name="citation_author"/> <meta content="Institute of Oncology, Fundación Santa Fe de Bogotá" name="citation_author_institution"/> <meta content="Ivan Solà" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010340.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010340.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010340.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010340.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized [*therapeutic use]; Clinical Trials, Phase III as Topic; Hemoglobinuria, Paroxysmal [*drug therapy]; Multicenter Studies as Topic; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010340.pub2&amp;doi=10.1002/14651858.CD010340.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WcPhDegp";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010340\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010340\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010340.pub2",title:"Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria",firstPublishedDate:"Oct 30, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010340.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010340.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010340.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010340.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010340.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010340.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010340.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010340.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010340.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010340.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3898 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010340.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-sec-0041"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-sec-0042"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/appendices#CD010340-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/table_n/CD010340StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/table_n/CD010340StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information#CD010340-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Arturo J Martí‐Carvajal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information#CD010340-cr-0003">Vidhu Anand</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information#CD010340-cr-0004">Andrés Felipe Cardona</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information#CD010340-cr-0005">Ivan Solà</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information/en#CD010340-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010340.pub2">https://doi.org/10.1002/14651858.CD010340.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010340-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010340-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010340-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010340-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010340-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010340-abs-0001" lang="en"> <section id="CD010340-sec-0001"> <h3 class="title" id="CD010340-sec-0001">Background</h3> <p>Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, not malignant, disease of the hematopoietic stem cells, associated with significant morbidity and mortality. It is a rare disease with an estimated incidence of 1.3 new cases per one million individuals per year. The treatment of PNH has been largely empirical and symptomatic, with blood transfusions, anticoagulation, and supplementation with folic acid or iron. Eculizumab, a biological agent that inhibits complement cascade, was developed for preventing hemolytic anemia and severe thrombotic episodes. </p> </section> <section id="CD010340-sec-0002"> <h3 class="title" id="CD010340-sec-0002">Objectives</h3> <p>To assess the clinical benefits and harms of eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (PNH). </p> </section> <section id="CD010340-sec-0003"> <h3 class="title" id="CD010340-sec-0003">Search methods</h3> <p>We conducted a comprehensive search strategy. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <i>The Cochrane Library</i> 2014, Issue 5), Ovid MEDLINE (from 1946 to 15 May 2014), EMBASE (from 1980 to 25 June 2014), and LILACS (from 1982 to 25 June 2014). We did not apply any language restrictions. </p> </section> <section id="CD010340-sec-0004"> <h3 class="title" id="CD010340-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) irrespective of their publication status or language. No limits were applied with respect to period of follow‐up. We excluded quasi‐RCTs. We included trials comparing eculizumab with placebo or best available therapy. We included any patient with a confirmed diagnosis of PNH. Primary outcome was overall survival. </p> </section> <section id="CD010340-sec-0005"> <h3 class="title" id="CD010340-sec-0005">Data collection and analysis</h3> <p>We independently performed a duplicate selection of eligible trials, risk of bias assessment, and data extraction. We estimated risk ratios (RRs) and 95% confidence interval (CIs) for dichotomous outcomes, and mean differences (MDs) and 95% CIs for continuous outcomes. We used a random‐effects model for analysis. </p> </section> <section id="CD010340-sec-0006"> <h3 class="title" id="CD010340-sec-0006">Main results</h3> <p>We identified one multicenter (34 sites) phase III RCT involving 87 participants. The trial compared eculizumab versus placebo, and was conducted in the US, Canada, Europe, and Australia with 26 weeks of follow‐up. This small trial had high risk of bias in many domains (attrition and selective reporting). It was sponsored by a pharmaceutical company. No patients died during the study. By using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (scores can range from 0 to 100, with higher scores on the global health status and functioning scales indicating improvement), the trial showed improvement in health‐related quality of life in patients treated with eculizumab (mean difference (MD) 19.4, 95% CI 8.25 to 30.55; P = 0.0007; low quality of evidence). By using the Functional Assessment of Chronic Illness Therapy Fatigue instrument (scores can range from 0 to 52, with higher scores indicating improvement in fatigue), the trial showed a reduction in fatigue (MD 10.4, 95% CI 9.97 to 10.83; P = 0.00001; moderate quality of evidence) in the eculizumab group compared with placebo. Eculizumab compared with placebo showed a greater proportion of patients with transfusion independence: 51% (22/43) versus 0% (0/44); risk ratio (RR) 46.02, 95% CI 2.88 to 735.53; P = 0.007; moderate quality of evidence; and withdrawal for any reason: 4.7% (2/43) versus 22.72% (10/44); RR 0.20, 95% CI 0.05 to 0.88; P = 0.03; moderate quality of evidence. Due to the low rate of events observed, the included trial did not show any difference between eculizumab and placebo in terms of serious adverse events: 9.3% (4/43) versus 20.4% (9/44); RR 0.15, 95% CI 0.15 to 1.37; P = 0.16; low quality of evidence. We did not observe any difference between intervention and placebo for the most frequent adverse events. One participant receiving placebo showed an episode of thrombosis. The trial did not assess overall survival, transformation to myelodysplastic syndrome and acute myelogenous leukemia, or development or recurrence of aplastic anemia on treatment. </p> </section> <section id="CD010340-sec-0007"> <h3 class="title" id="CD010340-sec-0007">Authors' conclusions</h3> <p>This review has detected an absence of evidence for eculizumab compared with placebo for treating paroxysmal nocturnal hemoglobinuria (PNH), in terms of overall survival, nonfatal thrombotic events, transformation to myelodysplastic syndrome and acute myelogenous leukemia, and development and recurrence of aplastic anemia on treatment. Current evidence indicates that compared with placebo, eculizumab increases health‐related quality of life and increases transfusion independence. During the execution of the included trial, no patients died. Furthermore, the intervention seems to reduce fatigue and withdrawals for any reason. The safety profile of eculizumab is unclear. These conclusions are based on one small trial with risk of attrition and selective reporting bias. </p> <p>Therefore, prescription of eculizumab for treating patients with PNH can neither be supported nor rejected, unless new evidence from a large high quality trial alters this conclusion. Therefore, we urge the reader to interpret the trial results with much caution. Future trials on this issue should be conducted according to the SPIRIT statement and reported according to the CONSORT statement by independent investigators, and using the Foundation of Patient‐Centered Outcomes Research recommendations. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010340-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010340-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010340-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010340-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010340-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010340-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010340-abs-0004" lang="en"> <h3>Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria</h3> <p><b>Review question</b> <br/> We reviewed the evidence about the effects of eculizumab for treating patients with paroxsymal nocturnal hemoglobinuria. </p> <p><b>Background</b> <br/> Paroxysmal nocturnal hemoglobinuria is a disorder of the hematopoietic stem cells (a cell that can self renew and differentiate into one or more cell types). It is characterized by episodes of intravascular hemolysis (destruction of red blood cells), and chronic hemolytic anemia. The intravascular destruction of red blood cells involves clinical findings in gastrointestinal, cardiovascular, pulmonary, cerebral, and urogenital systems, as well as clotting disorders.<br/> <br/> The treatment of paroxysmal nocturnal hemoglobinuria has been largely empirical and symptomatic, with packed red blood cell transfusions, anticoagulation, and supplementation with folic acid or iron. Many different pharmacological interventions that are used for treating this medical disorder are not standardized. Eculizumab is a newly available biological agent for preventing hemolytic anemia and severe clotting episodes. </p> <p><b>Study characteristics</b> <br/> We identified one study that included a limited number of patients comparing eculizumab with placebo. The study was published in 2006, and was conducted in the US, Canada, Europe, and Australia with 26 weeks of follow‐up. </p> <p><b>Key results</b> <br/> No patients died during the performance of this single study. The study showed a moderate improvement in the quality of life in patients treated with eculizumab. In addition, eculizumab reduced fatigue and the number of patients that withdrew from the study for any reason. Eculizumab showed a higher proportion of patients with transfusion independence. There was no difference between eculizumab and placebo in terms of adverse events, probably due to the low rate of events observed during the study. The trial did not assess other relevant outcomes such as overall survival, transformation to myelodysplastic syndrome and acute myelogenous leukemia, or development or recurrence of aplastic anemia on treatment. </p> <p><b>Quality of evidence</b> <br/> The confidence in the results is moderate to low. The study had limitations in its design and execution, and was sponsored by the manufacturer of the drug that was assessed. Moreover, the limited number of patients included in the study led to imprecise results. Larger studies should provide more information about the effect of eculizumab in patients with paroxsymal nocturnal hemoglobinuria. </p> <p>This plain language summary is current as of May 2014.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010340-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010340-sec-0089"></div> <h3 class="title" id="CD010340-sec-0090">Implications for practice</h3> <section id="CD010340-sec-0090"> <p>Regarding clinical effectiveness and harms, there is limited evidence of eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (PNH). The results are based on one small sponsored drug company RCT with a high risk of bias. Even though this trial reports no mortality; information is absent for the main clinical outcomes such as nonfatal thrombotic events, transformation to myelodysplastic syndrome and acute myelogenous leukemia, and development and recurrence of aplastic anemia. In addition, safety data remain unclear. Therefore, prescription of eculizumab for treating patients with PNH can neither be supported nor rejected, unless new evidence from a large high quality trial alters this conclusion. </p> </section> <h3 class="title" id="CD010340-sec-0091">Implications for research</h3> <section id="CD010340-sec-0091"> <p>This Cochrane review identified the need for well designed, adequately powered RCTs to assess the clinical benefits and harms of eculizumab on overall survival as the primary outcome in PNH. Potential trials should also include clinical outcomes such as health‐related quality of life and fatigue, all‐cause mortality, fatal or nonfatal thrombotic events, transformation to myelodysplastic syndrome and acute myelogenous leukemia, development and recurrence of aplastic anemia, and adverse events.<br/> <br/> For increasing external validity, potential trials should include any PNH‐category patients. The trial should be reported according to the Consolidated standards of reporting trials (CONSORT) statement for improving the quality of reporting of efficacy and to get better reports of harms in clinical research (<a href="./references#CD010340-bbs2-0097" title="IoannidisJP , EvansSJ , GotzschePC , O'NeillRT , AltmanDG , SchulzK , et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine2004;141(10):781‐8. [PUBMED: 15545678] ">Ioannidis 2004</a>; <a href="./references#CD010340-bbs2-0121" title="MoherD , HopewellS , SchulzKF , MontoriV , GotzschePC , DevereauxPJ , et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology2010;63(8):e1‐37. [PUBMED: 20346624] ">Moher 2010</a>; <a href="./references#CD010340-bbs2-0170" title="TurnerL , ShamseerL , AltmanDG , WeeksL , PetersJ , KoberT , et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database of Systematic Reviews2012, Issue 11 . [DOI: 10.1002/14651858.MR000030.pub2] ">Turner 2012</a>). Future trials should be planned according to the recommendations of Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (<a href="./references#CD010340-bbs2-0040" title="ChanAW , TetzlaffJM , GotzschePC , AltmanDG , MannH , BerlinJA , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ2013;346:e7586. [PUBMED: 23303884] ">Chan 2013</a>; <a href="./references#CD010340-bbs2-0041" title="ChanAW , TetzlaffJM , AltmanDG , LaupacisA , GotzschePC , Krleza‐JericK , et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine2013;158(3):200‐7. [PUBMED: 23295957] ">Chan 2013a</a>) and the Foundation of Patient‐Centered Outcomes Research (<a href="./references#CD010340-bbs2-0027" title="BaschE , AronsonN , BergA , FlumD , GabrielS , GoodmanSN , et al. Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636‐40. [PUBMED: 22511692] ">Basch 2012</a>; <a href="./references#CD010340-bbs2-0058" title="GabrielSE , NormandSL . Getting the Methods Right ‐ The Foundation of Patient‐Centered Outcomes Research. The New England Journal of Medicine2012;367(9):787‐90. [PUBMED: 22830434] ">Gabriel 2012</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010340-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010340-sec-0022"></div> <div class="table" id="CD010340-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Eculizumab compared with placebo for paroxysmal nocturnal hemoglobinuria</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Eculizumab compared with placebo for paroxysmal nocturnal hemoglobinuria</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with paroxysmal nocturnal hemoglobinuria<br/> <b>Intervention:</b> eculizumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Eculizumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> <br/> Follow‐up: at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No patients died during the execution of the included study. The small sample size of the included trial does not allow to make judgments about the quality of evidence </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome)<br/> Follow‐up: at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the health‐related quality of life score in the control group was<br/> <b>‐8.5</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the health‐related quality of life score in the intervention group was<br/> <b>19.4 higher</b> <br/> (8.25 to 30.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> <br/> Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐Fatigue). Scale from: 0 to 52 (a higher score means a better outcome)<br/> Follow‐up: data at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the fatigue score in the control group was<br/> <b>‐4.0 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the fatigue score in the intervention group was<br/> <b>10.4 higher</b> <br/> (9.97 to 10.83 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (serious and nonserious)</b> <br/> Medical Dictionary for Regulatory Activities (MedDRA)<br/> Follow‐up: data at 26 weeks of treatment<sup>2,9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>205 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> <br/> (31 to 280) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.45</b> <br/> (0.15 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion independence</b> <br/> Follow‐up: data at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>920 per 1000</b> <br/> (58 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 46.02</b> <br/> (2.88 to 735.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> <br/> Follow‐up: data at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> <br/> (11 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> <br/> (0.05 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk is based on the risks for the control group in the included trial.<br/> <sup>2</sup> In the TRIUMPH trial patients received treatment for 26 weeks.<br/> <sup>3</sup> Limitations in design and execution: Outcome assessment was performed in an open fashion (for subjective outcomes), and attrition in placebo group due to the perceived a lack of efficacy could bias the reported estimates.<br/> <sup>4</sup> Imprecision: Low sample size (87 participants) resulting in confidence intervals suggesting moderate to important changes in quality of life.<br/> <sup>5</sup> Imprecision: Low rate of adverse events (13 in total) resulting in wide confidence intervals; quality of evidence lowered by two levels due to very serious imprecision.<br/> <sup>6</sup> Assuming a control group risk of 2% (equivalent to one event in this group).<br/> <sup>7</sup> Imprecision: Low rate of adverse events (22 in total, none of them in control group) resulting in wide confidence intervals.<br/> <sup>8</sup> Imprecision: Low rate of adverse events (12 in total) resulting in wide confidence intervals.<br/> <sup>9</sup> Quality of evidence rated and effect estimates obtained for serious adverse effects. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010340-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010340-sec-0023"></div> <p>For a glossary of medical terms, see <a href="./appendices#CD010340-sec-0095">Appendix 1</a>. </p> <section id="CD010340-sec-0024"> <h3 class="title" id="CD010340-sec-0024">Description of the condition</h3> <p>Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder of the hematopoietic stem cells, but it is not a malignant disease (<a href="./references#CD010340-bbs2-0129" title="ParkerCJ . Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria. Hematology/Oncology Clinics of North America2009;23(2):333‐46. [PUBMED: 19327587] ">Parker 2009a</a>; <a href="./references#CD010340-bbs2-0132" title="ParkerCJ . Paroxysmal nocturnal hemoglobinuria. Current Opinion in Hematology2012;19(3):141‐8. [PUBMED: 22395662] ">Parker 2012</a>; <a href="./references#CD010340-bbs2-0137" title="PuJJ , BrodskyRA . Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clinical and Translational Science2011;4(3):219‐24. [PUBMED: 21707954] ">Pu 2011</a>). The first two cases were reported by William Gull and Paul Strübing between 1866 and 1882, respectively (<a href="./references#CD010340-bbs2-0146" title="RosseWF . Paroxysmal nocturnal hemoglobinuria: present status and future prospects. The Western Journal of Medicine1980;132(3):219‐28. [PUBMED: 7376658] ">Rosse 1980</a>; <a href="./references#CD010340-bbs2-0179" title="WilmannsJC . Paroxysmal nocturnal hemoglobinuria first described in 1882 by Paul Strubing: an example of cooperation between clinical and basic research. Blut1982;45(6):367‐73. [PUBMED: 6753969] ">Wilmanns 1982</a>). In 1925, Enneking introduced the term 'paroxysmal nocturnal hemoglobinuria' (<a href="./references#CD010340-bbs2-0035" title="BrodskyRA . Paroxysmal nocturnal hemoglobinuria, Chapter 30. In: HoffmanR , FurieB , BenzEJ , McGlaveP , SilbersteinLE , ShattilSJ editor(s). Hematology: Basic Principles and Practice. 5th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2009:385‐94. ">Brodsky 2009b</a>). The term 'nocturnal' is misleading, as the hemolysis can occur at any time (<a href="./references#CD010340-bbs2-0031" title="BrodskyRA . Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement‐related hemolytic anemia. Annals of Internal Medicine2008;148(8):587‐95. [PUBMED: 18413620] ">Brodsky 2008a</a>). </p> <p>PNH arises as a consequence of nonmalignant clonal expansion of one or more hematopoietic stem cells that have acquired a somatic mutation of the X chromosome gene called phosphatidylinositol glycan class A (PIGA) (<a href="./references#CD010340-bbs2-0030" title="BrodskyRA , HuR . PIG‐A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leukemia and Lymphoma2006;47(7):1215‐21. [PUBMED: 16923549] ">Brodsky 2006</a>; <a href="./references#CD010340-bbs2-0031" title="BrodskyRA . Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement‐related hemolytic anemia. Annals of Internal Medicine2008;148(8):587‐95. [PUBMED: 18413620] ">Brodsky 2008a</a>; <a href="./references#CD010340-bbs2-0132" title="ParkerCJ . Paroxysmal nocturnal hemoglobinuria. Current Opinion in Hematology2012;19(3):141‐8. [PUBMED: 22395662] ">Parker 2012</a>). The protein encoded by PIGA is essential for synthesis of the glycosyl phosphatidylinositol (GPI) moiety that serves as the membrane anchor for a functionally diverse group of cellular proteins. As a consequence of mutant PIGA, all GPI proteins are deficient on progeny of affected stem cells (<a href="./references#CD010340-bbs2-0132" title="ParkerCJ . Paroxysmal nocturnal hemoglobinuria. Current Opinion in Hematology2012;19(3):141‐8. [PUBMED: 22395662] ">Parker 2012</a>; <a href="./references#CD010340-bbs2-0144" title="RisitanoAM . Paroxysmal nocturnal hemoglobinuria and other complement‐mediated hematological disorders. Immunobiology2012;217(11):1080‐7. [PUBMED: 22964233] ">Risitano 2012</a>). Decay accelerating factor (CD‐55) and membrane inhibitor of reactive lysis (CD59) are complement regulatory proteins which are anchored to blood red cells surface (<a href="./references#CD010340-bbs2-0167" title="ThurmanJM . New anti‐complement drugs: not so far way. Blood2014;123(13):1975‐6. [PUBMED: 24677397] ">Thurman 2104</a>). These proteins interact with complement proteins, mainly C3b and C4b, and inhibit the convertase complexes thereby halting prolonged activation. The deficiency of CD55 and CD59 in PNH therefore results in prolonged and uncontrolled activation of the complement pathways, resulting in complement‐mediated intravascular hemolysis (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>). </p> <p>Diagnosis of PNH is based on the following criteria (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>). </p> <p> <ol id="CD010340-list-0001"> <li> <p>Evidence of a population of peripheral blood cells (erythrocytes, granulocytes, or preferably both) deficient in glycosylphosphatidylinositol–anchored proteins detected by flow cytometric analysis. </p> </li> <li> <p>Complete blood count, reticulocyte count, serum concentration of lactate dehydrogenase, bilirubin (fractionated), and haptoglobin. </p> </li> <li> <p>Bone marrow aspirate, biopsy, and cytogenetics.</p> </li> </ol> </p> <p>Currently, flow cytometry to detect populations of glycosylphosphatidylinositol‐anchored protein‐deficient cells is firmly established as the method of choice for diagnosis and monitoring paroxysmal hemoglobinuria (<a href="./references#CD010340-bbs2-0028" title="BorowitzMJ , CraigFE , DigiuseppeJA , IllingworthAJ , RosseW , SutherlandDR , et al. Clinical Cytometry Society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry Part B2010;78(4):211‐30. [PUBMED: 20533382] ">Borowitz 2010</a>; <a href="./references#CD010340-bbs2-0141" title="RichardsSJ , RawstronAC , HillmenP . Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry2000;42(4):223‐33. [PUBMED: 10934341] ">Richards 2000</a>). </p> <p>PNH is a rare disease with an estimated incidence of 1.3 new cases per one million individuals per year (<a href="./references#CD010340-bbs2-0028" title="BorowitzMJ , CraigFE , DigiuseppeJA , IllingworthAJ , RosseW , SutherlandDR , et al. Clinical Cytometry Society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry Part B2010;78(4):211‐30. [PUBMED: 20533382] ">Borowitz 2010</a>; <a href="./references#CD010340-bbs2-0031" title="BrodskyRA . Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement‐related hemolytic anemia. Annals of Internal Medicine2008;148(8):587‐95. [PUBMED: 18413620] ">Brodsky 2008a</a>; <a href="./references#CD010340-bbs2-0032" title="BrodskyRA . Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Reviews2008;22(2):65‐74. [PUBMED: 18063459] ">Brodsky 2008b</a>). </p> <p>According to the International Paroxysmal Nocturnal Hemoglobinuria Interest Group (I‐PIG), PNH is classified into three categories: </p> <p> <ol id="CD010340-list-0002"> <li> <p>classic PNH;</p> </li> <li> <p>PNH in the setting of another specified bone marrow disorder (e.g. PNH/aplastic anemia, or PNH/refractory anemia‐myelodysplastic syndrome); and </p> </li> <li> <p>PNH‐subclinical, in the setting of another specified bone marrow disorder (e.g. PNH‐subclinical/aplastic anemia) (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>; <a href="./references#CD010340-bbs2-0129" title="ParkerCJ . Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria. Hematology/Oncology Clinics of North America2009;23(2):333‐46. [PUBMED: 19327587] ">Parker 2009a</a>). </p> </li> </ol> </p> <section id="CD010340-sec-0025"> <h4 class="title">Classic PNH</h4> <p>Affected patients have clinical evidence of intravascular hemolysis (reticulocytosis, abnormally high concentration of serum lactate dehydrogenase and indirect bilirubin, and abnormally low concentration of serum haptoglobin), but without evidence of another defined bone marrow abnormality. A cellular marrow with erythroid hyperplasia and normal or near‐normal morphology, but without nonrandom karyotypic abnormalities, is related with classic PNH (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>). </p> </section> <section id="CD010340-sec-0026"> <h4 class="title">PNH in the setting of another specified bone marrow disorder</h4> <p>This subcategory have clinical and laboratory evidence of hemolysis showing concomitantly, or have had a history of, a defined underlying marrow abnormality. Bone marrow analysis and cytogenetics are used to determine if PNH arose in association with aplastic anemia, myelodysplastic syndrome, or other myelopathy (e.g. myelofibrosis). Nonrandom karyotypic abnormalities that are associated with a specific bone marrow abnormality may contribute diagnostically (e.g. abnormalities of chromosomes 5q, 7, and 20q are associated with myelodysplastic syndrome) (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>). </p> </section> <section id="CD010340-sec-0027"> <h4 class="title">PNH‐subclinical in the setting of another specified bone marrow disorder</h4> <p>The patients in this subcategory have no clinical or laboratory evidence of hemolysis. Small populations of glycosyl phosphatidylinositol–anchored protein–deficient hematopoietic cells (peripheral blood erythrocytes, granulocytes, or both) are detected by very sensitive flow cytometric analysis. It is observed in association with bone marrow failure syndromes, particularly aplastic anemia and refractory anemia‐myelodysplastic (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>). </p> </section> <section id="CD010340-sec-0028"> <h4 class="title">Nonhematological clinical findings</h4> <p>Patients with PNH show clinical findings in gastrointestinal, cardiovascular, pulmonary, cerebral, and urogenital systems, as well as clotting disorders which are mediated by the consumption of nitric oxide (<a href="./references#CD010340-bbs2-0147" title="RotherRP , BellL , HillmenP , GladwinMT . The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA2005;293(13):1653‐62. [PUBMED: 15811985] ">Rother 2005</a>; <a href="./references#CD010340-bbs2-0150" title="SavageWJ , BrodskyRA . New insights into paroxysmal nocturnal hemoglobinuria. Hematology2007;12(5):371‐6. [PUBMED: 17852463] ">Savage 2007</a>). It is associated with a hypercoagulable state (thrombosis) (<a href="./references#CD010340-bbs2-0018" title="al‐HakimM , KatirjiB , OsorioI , WeismanR . Cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria: report of two cases. Neurology1993;43(4):742‐6. [PUBMED: 8469333] ">al‐Hakim 1993</a>; <a href="./references#CD010340-bbs2-0022" title="AudebertHJ , PlanckJ , EisenburgM , SchrezenmeierH , HaberlRL . Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. Journal of Neurology2005;252(11):1379‐86. [PUBMED: 16021362] ">Audebert 2005</a>; <a href="./references#CD010340-bbs2-0026" title="BarbuiT , CarobbioA , CervantesF , VannucchiAM , GuglielmelliP , AntonioliE , et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood2010;115(4):778‐82. [PUBMED: 19965680] ">Barbui 2010</a>; <a href="./references#CD010340-bbs2-0050" title="DunphyCH , Sotelo‐AvilaC , LuisiriA , ChuJY . Paroxysmal nocturnal hemoglobinuria associated with venous thrombosis and papillary endothelial hyperplasia presenting as ulcerated duodenal mass. Archives of Pathology and Laboratory Medicine1994;118(8):837‐9. [PUBMED: 8060237] ">Dunphy 1994</a>; <a href="./references#CD010340-bbs2-0059" title="GayerG , Zandman‐GoddardG , RaananiP , HertzM , ApterS . Widespread abdominal venous thrombosis in paroxysmal nocturnal hemoglobinuria diagnosed on CT. Abdominal Imaging2001;26(4):414‐9. [PUBMED: 11441556] ">Gayer 2001</a>; <a href="./references#CD010340-bbs2-0096" title="InafukuT , HataT , AkutsuT , KandaT . Superior sagittal sinus thrombosis in paroxysmal nocturnal hemoglobinuria‐an autopsied case. Rinsho Shinkeigaku1993;33(4):427‐33. [PUBMED: 8370205] ">Inafuku 1993</a>). The main nonhematological clinical findings include acute or chronic renal failure (<a href="./references#CD010340-bbs2-0042" title="ChowKM , LaiFM , WangAY , ChanYL , TangNL , LiPK . Reversible renal failure in paroxysmal nocturnal hemoglobinuria. American Journal of Kidney Diseases2001;37(2):E17. [PUBMED: 11157403] ">Chow 2001</a>; <a href="./references#CD010340-bbs2-0046" title="deCharryC , deCharryF , LemoigneF , LamboleyJL , PasquetF , PavicM . Renal vein infarction, a complication of paroxysmal nocturnal hemoglobinuria [Infarctus renal veineux, une complication de l'hemoglobinurie paroxystique nocturne]. Nephrologie and Therapeutique2012;8(7):537‐9. [PUBMED: 22609136] ">de Charry 2012</a>; <a href="./references#CD010340-bbs2-0064" title="GuaschA . Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010; Vol. 85, issue 8:551‐2. [PUBMED: 20658585] ">Guasch 2010</a>; <a href="./references#CD010340-bbs2-0092" title="HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] ">Hillmen 2010</a>; <a href="./references#CD010340-bbs2-0099" title="JacksonGH , NobleRS , MaungZT , MainJ , SmithSR , ReidMM . Severe haemolysis and renal failure in a patient with paroxysmal nocturnal haemoglobinuria. Journal of Clinical Pathology1992;45(2):176‐7. [PUBMED: 1541704] ">Jackson 1992</a>; <a href="./references#CD010340-bbs2-0124" title="NairRK , KhairaA , SharmaA , MahajanS , DindaAK . Spectrum of renal involvement in paroxysmal nocturnal hemoglobinuria: report of three cases and a brief review of the literature. International Urology and Nephrology2008;40(2):471‐5. [PUBMED: 18368508] ">Nair 2008</a>; <a href="./references#CD010340-bbs2-0158" title="SechiLA , MariglianoA , TeddeR . Venous thrombosis and acute renal failure in paroxysmal nocturnal haemoglobinuria. Nephrology, Dialysis, Transplantation1988; Vol. 3, issue 5:708‐9. [PUBMED: 3146740] ">Sechi 1988</a>), pulmonary hypertension (<a href="./references#CD010340-bbs2-0081" title="HellerPG , GrinbergAR , LencioniM , MolinaMM , RoncoroniAJ . Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest1992;102(2):642‐3. [PUBMED: 1643968] ">Heller 1992</a>; <a href="./references#CD010340-bbs2-0119" title="MisztalT , TomasiakM . Pathophysiological consequences of hemolysis. Role of cell‐free hemoglobin [Patofizjologiczne Konsekwencje Hemolizy. Rola Wolnej Hemoglobiny]. Postepy Higieny i Medycyny Doswiadczalnej2011;65:627‐39. [PUBMED: 22100795] ">Misztal 2011</a>), and an increasing risk for splanchnic vein thrombosis syndrome called Budd‐Chiari (<a href="./references#CD010340-bbs2-0062" title="GrahamML , RosseWF , HalperinEC , MillerCR , WareRE . Resolution of Budd‐Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. British Journal of Haematology1996;92(3):707‐10. [PUBMED: 8616041] ">Graham 1996</a>; <a href="./references#CD010340-bbs2-0080" title="HauserAC , BrichtaA , Pabinger‐FaschingI , JagerU . Fibrinolytic therapy with rt‐PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd‐Chiari syndrome. Annals of Hematology2003;82(5):299‐302. [PUBMED: 12707719] ">Hauser 2003</a>; <a href="./references#CD010340-bbs2-0100" title="JainP . An unusual cause of Budd‐Chiari syndrome: paroxysmal nocturnal hemoglobinuria. Journal of Gastrointestinal and Liver Diseases2010; Vol. 19, issue 1:107‐8. [PUBMED: 20361088] ">Jain 2010</a>; <a href="./references#CD010340-bbs2-0102" title="Jimenez MarcoM , Garcia GrandeA , Canales AlbendeaM , Fernandez‐PrietoA , Hernandez NavarroF . The Budd‐Chiari syndrome coinciding with a hemolytic crisis in a patient with paroxysmal nocturnal hemoglobinuria [Sindrome de Budd‐Chiari coincidiendo con crisis hemolítica en paciente con hemoglobinuria paroxística nocturna]. Revista Clinica Española1999; Vol. 199, issue 1:50‐1. [PUBMED: 10089784] ">Jimenez 1999</a>; <a href="./references#CD010340-bbs2-0093" title="HoekstraJ , LeebeekFW , PlessierA , RaffaS , Darwish MuradS , HellerJ , et al. Paroxysmal nocturnal hemoglobinuria in Budd‐Chiari syndrome: findings from a cohort study. Journal of Hepatology2009;51(4):696‐706. [PUBMED: 19664836] ">Hoekstra 2009</a>; <a href="./references#CD010340-bbs2-0168" title="TorresJ , DeVroeyB , NoelMP , NotteghemB , ColombelJF . Recurrent small bowel ischemia in a patient with paroxysmal nocturnal hemoglobinuria. Nature Reviews. Gastroenterology and Hepatology2010;7(7):410‐4. [PUBMED: 20440280] ">Torres 2010</a>; <a href="./references#CD010340-bbs2-0183" title="YinDL , LiuLX , ZhangSG , TianLT , LuZY , JiangHC . Portal hypertension resulted from paroxysmal nocturnal hemoglobinuria: a case report and review of literature. International Journal of Hematology2009;89(3):302‐4. [PUBMED: 19319631] ">Yin 2009</a>). Visceral thrombosis, cerebrovascular events and pulmonary embolism predict a poor outcome (<a href="./references#CD010340-bbs2-0184" title="ZiakasPD , PoulouLS , PomoniA . Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Current Vascular Pharmacology2008;6(4):347‐53. [PUBMED: 18855722] ">Ziakas 2008</a>). The exact reason for an increase of thrombosis risk in patients with PNH is unknown (<a href="./references#CD010340-bbs2-0035" title="BrodskyRA . Paroxysmal nocturnal hemoglobinuria, Chapter 30. In: HoffmanR , FurieB , BenzEJ , McGlaveP , SilbersteinLE , ShattilSJ editor(s). Hematology: Basic Principles and Practice. 5th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2009:385‐94. ">Brodsky 2009b</a>; <a href="./references#CD010340-bbs2-0171" title="vanBijnenST , VanHeerdeWL , MuusP . Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. Journal of Thrombosis and Haemostasis2012;10(1):1‐10. [PUBMED: 22077430] ">van Bijnen 2012a</a>). However, a major role of complement activation has been suggested to explain this clinical finding (<a href="./references#CD010340-bbs2-0172" title="vanBijnenST , vanRijnRS , KoljenovicS , TeBoekhorstP , deWitteT , MuusP . Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab. British Journal of Haematology2012; Vol. 157, issue 6:762‐3. [PUBMED: 22372429] ">van Bijnen 2012b</a>). </p> </section> <section id="CD010340-sec-0029"> <h4 class="title">Prognosis (overall survival)</h4> <p>PNH is a chronic disorder associated with significant morbidity and mortality (<a href="./references#CD010340-bbs2-0078" title="HarrisJW , KoscickR , LazarusHM , EshlemanJR , MedofME . Leukemia arising out of paroxysmal nocturnal hemoglobinuria. Leukemia and Lymphoma1999;32(5‐6):401‐26. [PUBMED: 10048414] ">Harris 1999</a>; <a href="./references#CD010340-bbs2-0082" title="Hernandez‐CampoPM , AlmeidaJ , OrfaoA . Paroxysmal nocturnal hemoglobinuria [Hemoglobinuria paroxística nocturna]. Medicina Clinica2008;131(16):617‐30. [PUBMED: 19080854] ">Hernandez‐Campo 2008</a>; <a href="./references#CD010340-bbs2-0138" title="RachidiS , MusallamKM , TaherAT . A closer look at paroxysmal nocturnal hemoglobinuria. European Journal of Internal Medicine2010;21(4):260‐7. [PUBMED: 20603032] ">Rachidi 2010</a>). The overall survival at 10 years after diagnosis with PNH has been variously estimated to be 65% (<a href="./references#CD010340-bbs2-0160" title="SociéG , MaryJY , deGramontA , RioB , LeporrierM , RoseC , et al. Paroxysmal nocturnal haemoglobinuria: long‐term follow‐up and prognostic factors. French Society of Haematology. Lancet1996;348(9027):573‐7. [PUBMED: 8774569] ">Socié 1996</a>), 77.6% (<a href="./references#CD010340-bbs2-0060" title="GeM , LiX , ShiJ , ShaoY , ZhengY . Clinical features and prognostic factors of Asian patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. Annals of Hematology2012;91(7):1121‐8. [PUBMED: 22281992] ">Ge 2012</a>), and 68% (<a href="./references#CD010340-bbs2-0169" title="TudelaM , JarqueI , Perez‐SirventML , PalauJ , SanzMA . Clinical profile and course of paroxysmal nocturnal hemoglobinuria [Perfil clínico y evolutivo de la hemoglobinuria paroxística nocturna]. Sangre1993;38(4):301‐7. [PUBMED: 8235945] ">Tudela 1993</a>). </p> </section> </section> <section id="CD010340-sec-0030"> <h3 class="title" id="CD010340-sec-0030">Description of the intervention</h3> <p>The treatment of PNH has been largely empirical and symptomatic, with blood transfusions, anticoagulation, and supplementation with folic acid or iron (<a href="./references#CD010340-bbs2-0113" title="LuzzattoL , GianfaldoniG , NotaroR . Management of paroxysmal nocturnal haemoglobinuria: a personal view. British Journal of Haematology2011;153(6):709‐20. [PUBMED: 21517820] ">Luzzatto 2011</a>; <a href="./references#CD010340-bbs2-0149" title="RöthA , DuhrsenU . Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. European Journal of Haematology2011;87(6):473‐9. [PUBMED: 21883481] ">Röth 2011</a>). These interventions are mainly aimed to alleviate anemia and thrombotic episodes. The interventions include pharmacological and nonpharmacological interventions. </p> <section id="CD010340-sec-0031"> <h4 class="title">A) Interventions for treating hemolytic anemia and diminished hematopoiesis</h4> <section id="CD010340-sec-0032"> <h5 class="title">Pharmacological interventions</h5> <p> <ol id="CD010340-list-0003"> <li> <p>Glucocorticoids (prednisone) and adrenocorticotropic hormone (ACTH) (<a href="./references#CD010340-bbs2-0029" title="BourantasK . High‐dose recombinant human erythropoietin and low‐dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta Haematologica1994;91(2):62‐5. [PUBMED: 8023644] ">Bourantas 1994</a>; <a href="./references#CD010340-bbs2-0054" title="Etienne‐MartinP , ClotM , KleppingJ , TroubatM , KleppingC . First case of Marchiafava‐Micheli syndrome treated and cured by ACTH [Premier cas de syndrome de Marchiafava‐Micheli traite et gueri par l'ACTH]. Bulletins et Memoires de la Societe Medicale des Hopitaux de Paris1954;70(11‐12):371‐4. [PUBMED: 13172623] ">Etienne‐Martin 1954</a>; <a href="./references#CD010340-bbs2-0056" title="FirkinF , GoldbergH , FirkinBG . Glucocorticoid management of paroxysmal nocturnal haemoglobinuria. Australasian Annals of Medicine1968;17(2):127‐34. [PUBMED: 5668172] ">Firkin 1968</a>; <a href="./references#CD010340-bbs2-0057" title="FunderbergH , PalmerWL , KirsnerJB . Paroxysmal nocturnal hemoglobinuria; report of a case with rare hemoglobinuria treated with corticotropin. The American Journal of the Medical Sciences1954;227(1):32‐8. [PUBMED: 13114212] ">Funderberg 1954</a>; <a href="./references#CD010340-bbs2-0094" title="HoffmanBJ , PowellVE . Paroxysmal nocturnal hemoglobinuria treated with ACTH without benefit. Blood1952;7(10):1038‐41. [PUBMED: 12977835] ">Hoffman 1952</a>; <a href="./references#CD010340-bbs2-0110" title="LeonardiP , LocatelliC . Marchiafava‐Micheli hemolytic anemia; results of treatment with ACTH, cortisone and transfusion of erythrocytes [Anemia emolitica di Marchiafava‐Micheli; risultati del trattamento con ACTH, cortisone e trasfusioni di emazie]. Acta Medica Patavina1955;15(3):366‐96. [PUBMED: 13394164] ">Leonardi 1955</a>). Prednisone is effective in hemolytic anemia but does not affect the hematopoiesis and the effective doses are generally higher (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>). </p> </li> <li> <p>Danazol (<a href="./references#CD010340-bbs2-0077" title="HarringtonWJSr , KolodnyL , HorstmanLL , JyW , AhnYS . Danazol for paroxysmal nocturnal hemoglobinuria. American Journal of Hematology1997;54(2):149‐54. [PUBMED: 9034290] ">Harrington 1997</a>; <a href="./references#CD010340-bbs2-0123" title="MurakawaM , ShibuyaT , HaradaM , OkamuraT , AsanoY , OkamuraH , et al. Danazol treatment for paroxysmal nocturnal hemoglobinuria. Japanese Journal of Medicine1990;29(4):417‐22. [PUBMED: 2273626] ">Murakawa 1990</a>). </p> </li> <li> <p>Erythropoietin (<a href="./references#CD010340-bbs2-0021" title="AstoriC , BonfichiM , PagnuccoG , BernasconiP , LazzarinoM , OrlandiE , et al. Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay. British Journal of Haematology1997;97(3):586‐8. [PUBMED: 9207404] ">Astori 1997</a>; <a href="./references#CD010340-bbs2-0024" title="BalleariE , MareniC , MarmontAM , GhioR . Therapy with recombinant erythropoietin in paroxysmal nocturnal haemoglobinuria. British Journal of Haematology1996; Vol. 94, issue 2:424. [PUBMED: 8759911] ">Balleari 1996b</a>; <a href="./references#CD010340-bbs2-0023" title="BalleariE , GattiAM , MareniC , MassaG , MarmontAM , GhioR . Recombinant human erythropoietin for long‐term treatment of anemia in paroxysmal nocturnal hemoglobinuria. Haematologica1996;81(2):143‐7. [PUBMED: 8641643] ">Balleari 1996a</a>; <a href="./references#CD010340-bbs2-0029" title="BourantasK . High‐dose recombinant human erythropoietin and low‐dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta Haematologica1994;91(2):62‐5. [PUBMED: 8023644] ">Bourantas 1994</a>; <a href="./references#CD010340-bbs2-0118" title="McMullinMF , HillmenP , ElderGE , LappinTR , LuzzattoL . Serum erythropoietin levels in paroxysmal nocturnal haemoglobinuria: implications for therapy. British Journal of Haematology1996;92(4):815‐7. [PUBMED: 8616071] ">McMullin 1996</a>). Higher doses of erythropoietin and its derivatives may be beneficial, particularly if renal impairment is also present. </p> </li> <li> <p>Iron replacement therapy when iron stores are deficient, and folic acid supplementation because of the high red cell turnover in these patients. </p> </li> <li> <p>Immunosuppressive therapy such as antithymocyte globulin and cyclosporine (<a href="./references#CD010340-bbs2-0051" title="EbenbichlerCF , WurznerR , SandhoferAD , NiederwieserD , DierichMP , PatschJR . Anti‐thymocyte globulin treatment of a patient for paroxysmal nocturnal haemoglobinuria‐aplastic anaemia syndrome: complement activation and transient decrease of the PNH clone. Immunobiology1996;196(5):513‐21. [PUBMED: 9145329] ">Ebenbichler 1996</a>; <a href="./references#CD010340-bbs2-0125" title="NakasoneH , IijimaK , AsanoH , NakamuraF , KidaM , IzutsuK , et al. Immunosuppressive therapy with antithymocyte globulin and cyclosporine for paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki2008;49(7):498‐504. [PUBMED: 18709982] ">Nakasone 2008</a>; <a href="./references#CD010340-bbs2-0126" title="PaquetteRL , YoshimuraR , VeisehC , KunkelL , GajewskiJ , RosenPJ . Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. British Journal of Haematology1997;96(1):92‐7. [PUBMED: 9012693] ">Paquette 1997</a>; <a href="./references#CD010340-bbs2-0153" title="ScheinbergP , MarteM , NunezO , YoungNS . Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti‐thymocyte globulin plus cyclosporine. Haematologica2010;95(7):1075‐80. [PUBMED: 20595102] ">Scheinberg 2010</a>). The immunosuppressive agents are an alternative to hematopoietic cell transplantation for aplastic anemia. However, the hemolytic components remain unchanged. </p> </li> <li> <p>Recombinant granulocyte stimulating factor alone or in combination with cyclosporine in PNH granulocytopenic patients (<a href="./references#CD010340-bbs2-0101" title="JegoP , LeStratA , GirardL , SebillotM , GrosboisB , LeBlayR , et al. Paroxysmal nocturnal hemoglobinuria: efficacy of prolonged treatment with granulocyte colony‐stimulating factor. Blood1997; Vol. 90, issue 7:2841‐3. [PUBMED: 9326254] ">Jego 1997</a>; <a href="./references#CD010340-bbs2-0156" title="SchubertJ , ScholzC , GeisslerRG , GanserA , SchmidtRE . G‐CSF and cyclosporin induce an increase of normal cells in hypoplastic paroxysmal nocturnal hemoglobinuria. Annals of Hematology1997;74(5):225‐30. [PUBMED: 9200995] ">Schubert 1997</a>). </p> </li> </ol> </p> </section> <section id="CD010340-sec-0033"> <h5 class="title">Nonpharmacological interventions</h5> <p> <ol id="CD010340-list-0004"> <li> <p>Washed red blood cell transfusion (<a href="./references#CD010340-bbs2-0063" title="GuaschJ . Indications for whole blood transfusion or erythrocyte concentrates and transfusion of washed erythrocytes with or without simultaneous heparin administration in paroxysmal nocturnal hemoglobinuria (HPN) [Indicaciones de la transfusión de sangre total o de concentrado de hematíes y de la infusion de hematíes lavados con o sin administración simultánea de heparina, en la hemoglobinuria paroxística nocturna (HPN)]. Sangre1969;14(3):358‐61. [PUBMED: 5406587] ">Guasch 1969</a>; <a href="./references#CD010340-bbs2-0099" title="JacksonGH , NobleRS , MaungZT , MainJ , SmithSR , ReidMM . Severe haemolysis and renal failure in a patient with paroxysmal nocturnal haemoglobinuria. Journal of Clinical Pathology1992;45(2):176‐7. [PUBMED: 1541704] ">Jackson 1992</a>). </p> </li> <li> <p>Allogeneic hematopoietic stem cell transplantation can cure classic PNH, but treatment‐related toxicity suggests caution for this management approach (<a href="./references#CD010340-bbs2-0019" title="AntinJH , GinsburgD , SmithBR , NathanDG , OrkinSH , RappeportJM . Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood1985;66(6):1247‐50. [PUBMED: 3904867] ">Antin 1985</a>; <a href="./references#CD010340-bbs2-0062" title="GrahamML , RosseWF , HalperinEC , MillerCR , WareRE . Resolution of Budd‐Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. British Journal of Haematology1996;92(3):707‐10. [PUBMED: 8616041] ">Graham 1996</a>; <a href="./references#CD010340-bbs2-0103" title="KawaharaK , WitherspoonRP , StorbR . Marrow transplantation for paroxysmal nocturnal hemoglobinuria. American Journal of Hematology1992;39(4):283‐8. [PUBMED: 1553957] ">Kawahara 1992</a>; <a href="./references#CD010340-bbs2-0108" title="LeeJL , LeeJH , LeeJH , ChoiSJ , KimS , SeolM , et al. Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria. European Journal of Haematology2003;71(2):114‐8. [PUBMED: 12890150] ">Lee 2003</a>; <a href="./references#CD010340-bbs2-0115" title="Matos‐FernandezNA , Abou MouradYR , CaceresW , Kharfan‐DabajaMA . Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biology of Blood and Marrow Transplantation2009;15(6):656‐61. [PUBMED: 19450749] ">Matos‐Fernandez 2009</a>; <a href="./references#CD010340-bbs2-0131" title="ParkerCJ . Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Hematology2011;2011:21‐9. [PUBMED: 22160008] ">Parker 2011</a>; <a href="./references#CD010340-bbs2-0139" title="RaiolaAM , VanLintMT , LamparelliT , GualandiF , BenvenutoF , FigariO , et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica2000;85(1):59‐62. [PUBMED: 10629593] ">Raiola 2000</a>; <a href="./references#CD010340-bbs2-0149" title="RöthA , DuhrsenU . Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. European Journal of Haematology2011;87(6):473‐9. [PUBMED: 21883481] ">Röth 2011</a>; <a href="./references#CD010340-bbs2-0181" title="WoodardP , WangW , PittsN , BenaimE , HorwitzE , CunninghamJ , et al. Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplantation2001;27(6):589‐92. [PUBMED: 11319587] ">Woodard 2001</a>). It has been suggested as a therapeutic option in life threatening and resistant disease associated with aplastic anemia, significant neutropenia and thrombocytopenia and severe thrombotic episodes. This treatment is used in every pediatric PNH patient with bone marrow failure, since children tolerate it better than adults (<a href="./references#CD010340-bbs2-0173" title="van denHeuvel‐EibrinkMM , BrediusRG , teWinkelML , TammingaR , deKrakerJ , Schouten‐van MeeterenAY , et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. British Journal of Haematology2005;128(4):571‐7. [PUBMED: 15686469] ">van den Heuvel‐Eibrink 2005</a>). </p> </li> </ol> </p> </section> </section> <section id="CD010340-sec-0034"> <h4 class="title">B) Interventions for treating thrombotic episodes</h4> <section id="CD010340-sec-0035"> <h5 class="title">Pharmacological interventions</h5> <p> <ol id="CD010340-list-0005"> <li> <p>Glucocorticoids (prednisone) (<a href="./references#CD010340-bbs2-0056" title="FirkinF , GoldbergH , FirkinBG . Glucocorticoid management of paroxysmal nocturnal haemoglobinuria. Australasian Annals of Medicine1968;17(2):127‐34. [PUBMED: 5668172] ">Firkin 1968</a>). </p> </li> <li> <p>Anticoagulant: heparin (<a href="./references#CD010340-bbs2-0052" title="EmadiA , BrodskyRA . Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2009; Vol. 84, issue 10:699‐701. [PUBMED: 19705437] ">Emadi 2009</a>), and warfarin (<a href="./references#CD010340-bbs2-0076" title="HallC , RichardsS , HillmenP . Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood2003;102(10):3587‐91. [PUBMED: 12893760] ">Hall 2003</a>). </p> </li> <li> <p>Thrombolytic therapy (<a href="./references#CD010340-bbs2-0020" title="AratenDJ , NotaroR , ThalerHT , KernanN , BouladF , Castro‐MalaspinaH , et al. Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica2012;97(3):344‐52. [PUBMED: 22133780] ">Araten 2012</a>; <a href="./references#CD010340-bbs2-0080" title="HauserAC , BrichtaA , Pabinger‐FaschingI , JagerU . Fibrinolytic therapy with rt‐PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd‐Chiari syndrome. Annals of Hematology2003;82(5):299‐302. [PUBMED: 12707719] ">Hauser 2003</a>; <a href="./references#CD010340-bbs2-0117" title="McMullinMF , HillmenP , JacksonJ , GanlyP , LuzzattoL . Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria. Journal of Internal Medicine1994;235(1):85‐9. [PUBMED: 8283166] ">McMullin 1994</a>; <a href="./references#CD010340-bbs2-0159" title="SholarPW , BellWR . Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria. Annals of Internal Medicine1985;103(4):539‐41. [PUBMED: 4037558] ">Sholar 1985</a>; <a href="./references#CD010340-bbs2-0162" title="TaniguchiK , OkadaM , YoshiharaS , SawadaA , TokugawaT , IshiiS , et al. Strategy for bone marrow transplantation in eculizumab‐treated paroxysmal nocturnal hemoglobinuria. International Journal of Hematology2011;94(4):403‐7. [PUBMED: 21927799] ">Taniguchi 2011</a>). </p> </li> </ol> </p> </section> <section id="CD010340-sec-0036"> <h5 class="title">Nonpharmacological interventions</h5> <p> <ol id="CD010340-list-0006"> <li> <p>Whole blood or packed red blood cell transfusion (<a href="./references#CD010340-bbs2-0063" title="GuaschJ . Indications for whole blood transfusion or erythrocyte concentrates and transfusion of washed erythrocytes with or without simultaneous heparin administration in paroxysmal nocturnal hemoglobinuria (HPN) [Indicaciones de la transfusión de sangre total o de concentrado de hematíes y de la infusion de hematíes lavados con o sin administración simultánea de heparina, en la hemoglobinuria paroxística nocturna (HPN)]. Sangre1969;14(3):358‐61. [PUBMED: 5406587] ">Guasch 1969</a>). </p> </li> <li> <p>Allogeneic hematopoietic stem cell transplantation (<a href="./references#CD010340-bbs2-0062" title="GrahamML , RosseWF , HalperinEC , MillerCR , WareRE . Resolution of Budd‐Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. British Journal of Haematology1996;92(3):707‐10. [PUBMED: 8616041] ">Graham 1996</a>; <a href="./references#CD010340-bbs2-0174" title="VergniolJ , LaharieD , DrouillardJ , EtienneG , PigneuxA , PlessierA , et al. Paroxysmal nocturnal hemoglobinuria and Budd‐Chiari syndrome: therapeutic challenge with bone marrow transplantation, transjugular intrahepatic portosystemic shunt, and vena cava stent. European Journal of Gastroenterology and Hepatology2005;17(4):453‐6. [PUBMED: 15756100] ">Vergniol 2005</a>). </p> </li> </ol> </p> </section> </section> <section id="CD010340-sec-0037"> <h4 class="title">C) Pharmacological intervention for preventing hemolytic anemia and severe thrombotic episodes </h4> <p>Eculizumab is a new targeted and disease‐modifying treatment strategy that inhibits a section of the complement cascade (<a href="./references#CD010340-bbs2-0045" title="DavisJ . Eculizumab. American Journal of Health‐System Pharmacy2008;65(17):1609‐15. [PUBMED: 18714106] ">Davis 2008</a>; <a href="./references#CD010340-bbs2-0086" title="HillA . Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Clinical Advances in Hematology and Oncology2005;3(11):849‐50. [PUBMED: 16491626] ">Hill 2005a</a>; <a href="./references#CD010340-bbs2-0111" title="LindorferMA , PawluczkowyczAW , PeekEM , HickmanK , TaylorRP , ParkerCJ . A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement‐mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood2010;115(11):2283‐91. [PUBMED: 20068220] ">Lindorfer 2010</a>; <a href="./references#CD010340-bbs2-0112" title="LuzzattoL , RisitanoAM , NotaroR . Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica2010; Vol. 95, issue 4:523‐6. [PUBMED: 20378572] ">Luzzatto 2010</a>; <a href="./references#CD010340-bbs2-0145" title="RisitanoAM . Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Advances in Experimental Medicine and Biology2013;734:155‐72. [PUBMED: 22990701] ">Risitano 2013</a>; <a href="./references#CD010340-bbs2-0148" title="RotherRP , RollinsSA , MojcikCF , BrodskyRA , BellL . Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology2007;25(11):1256‐64. [PUBMED: 17989688] ">Rother 2007</a>; <a href="./references#CD010340-bbs2-0154" title="SchrezenmeierH , HochsmannB . Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Expert Review of Hematology2009;2(1):7‐16. [PUBMED: 21082989] ">Schrezenmeier 2009</a>; <a href="./references#CD010340-bbs2-0155" title="SchrezenmeierH , HochsmannB . Drugs that inhibit complement. Transfusion and Apheresis Science2012;46(1):87‐92. [PUBMED: 22169380] ">Schrezenmeier 2012</a>; <a href="./references#CD010340-bbs2-0163" title="ThompsonCA . FDA approves drug to treat rare hemoglobinuria. American Journal of Health‐System Pharmacy2007; Vol. 64, issue 9:906. [PUBMED: 17468139] ">Thompson 2007</a>; <a href="./references#CD010340-bbs2-0182" title="WoodruffTM , NandakumarKS , TedescoF . Inhibiting the C5‐C5a receptor axis. Molecular Immunology2011;48(14):1631‐42. [PUBMED: 21549429] ">Woodruff 2011</a>; <a href="./references#CD010340-bbs2-0176" title="WeitzIC , RazaviP , RochandaL , ZwickerJ , FurieB , ManlyD , et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thrombosis Research2012;130(3):361‐8. [PUBMED: 22542362] ">Weitz 2012</a>). This drug effectively inhibits the formation of the membrane attack complex and intravascular hemolysis (<a href="./references#CD010340-bbs2-0155" title="SchrezenmeierH , HochsmannB . Drugs that inhibit complement. Transfusion and Apheresis Science2012;46(1):87‐92. [PUBMED: 22169380] ">Schrezenmeier 2012</a>; <a href="./references#CD010340-bbs2-0176" title="WeitzIC , RazaviP , RochandaL , ZwickerJ , FurieB , ManlyD , et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thrombosis Research2012;130(3):361‐8. [PUBMED: 22542362] ">Weitz 2012</a>; <a href="./references#CD010340-bbs2-0182" title="WoodruffTM , NandakumarKS , TedescoF . Inhibiting the C5‐C5a receptor axis. Molecular Immunology2011;48(14):1631‐42. [PUBMED: 21549429] ">Woodruff 2011</a>). Eculizumab has shown significant efficacy with a marked decrease in anemia, fatigue, transfusion requirements, renal impairment, pulmonary hypertension, and risk of severe thromboembolic events, ultimately resulting in improved quality of life and survival (<a href="./references#CD010340-bbs2-0033" title="BrodskyRA , YoungNS , AntonioliE , RisitanoAM , SchrezenmeierH , SchubertJ , et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood2008;111(4):1840‐7. [PUBMED: 18055865] ">Brodsky 2008c</a>; <a href="./references#CD010340-bbs2-0035" title="BrodskyRA . Paroxysmal nocturnal hemoglobinuria, Chapter 30. In: HoffmanR , FurieB , BenzEJ , McGlaveP , SilbersteinLE , ShattilSJ editor(s). Hematology: Basic Principles and Practice. 5th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2009:385‐94. ">Brodsky 2009b</a>; <a href="./references#CD010340-bbs2-0086" title="HillA . Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Clinical Advances in Hematology and Oncology2005;3(11):849‐50. [PUBMED: 16491626] ">Hill 2005a</a>; <a href="./references#CD010340-bbs2-0087" title="HillA , HillmenP , RichardsSJ , ElebuteD , MarshJC , ChanJ , et al. Sustained response and long‐term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood2005;106(7):2559‐65. [PUBMED: 15985537] ">Hill 2005b</a>; <a href="./references#CD010340-bbs2-0089" title="HillA , RotherRP , ArnoldL , KellyR , CullenMJ , RichardsSJ , et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low‐level extravascular hemolysis occurring through C3 opsonization. Haematologica2010;95(4):567‐73. [PUBMED: 20145265] ">Hill 2010a</a>; <a href="./references#CD010340-bbs2-0090" title="HillA , RotherRP , WangX , MorrisSMJr , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] ">Hill 2010b</a>; <a href="./references#CD010340-bbs2-0091" title="HillmenP , HallC , MarshJC , ElebuteM , BombaraMP , PetroBE , et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2004;350(6):552‐9. [PUBMED: 14762182] ">Hillmen 2004</a>; <a href="./references#CD010340-bbs2-0006" title="HillmenP , MuusP , DührsenU , RisitanoAM , SchubertJ , YoungNS . The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:123. ">Hillmen 2006</a>; <a href="./references#CD010340-bbs2-0009" title="KellyRJ , HillA , ArnoldLM , BrooksbankGL , RichardsSJ , CullenM , et al. Long‐term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood2011;117(25):6786‐92. [PUBMED: 21460245] ">Kelly 2011</a>; <a href="./references#CD010340-bbs2-0157" title="SchubertJ , HillmenP , RothA , YoungNS , ElebuteMO , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] ">Schubert 2008</a>). There is a need to establish the precise indications for starting treatment with eculizumab, its prophylactic role in thrombotic complications and the consideration of other available choices which include allogeneic hematopoietic cell transplantation and immunosuppressive regimens. </p> <section id="CD010340-sec-0038"> <h5 class="title">Clinical pharmacology of eculizumab</h5> <p>Treatment with eculizumab consists of an infusion of 600 mg over 25 to 45 minutes once a week for four weeks, followed by 900 mg in the fifth week. After this, the dose is maintained at 900 mg, given approximately every two weeks (<a href="./references#CD010340-bbs2-0053" title="European Medicines Agency. Eculizumab. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000791/WC500054210.pdf (accessed 4 September 2005). ">EMEA 2012</a>). Adverse events like fever, headache, back pain, nasopharyngitis, urinary tract infections, respiratory tract infections, gastrointestinal infections, nausea, fatigue, syncope, accelerated hypertension, infusion reactions, and life‐threatening desquamating rash have been reported in patients receiving eculizumab (<a href="./references#CD010340-bbs2-0048" title="DmytrijukA , Robie‐SuhK , CohenMH , RievesD , WeissK , PazdurR . FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. The Oncologist2008;13(9):993‐1000. [PUBMED: 18784156] ">Dmytrijuk 2008</a>; <a href="./references#CD010340-bbs2-0106" title="KnollBM , LetendreL , SteensmaDP . Life‐threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2008; Vol. 83, issue 11:881‐3. [PUBMED: 18756538] ">Knoll 2008</a>). </p> <p>Eculizumab was approved by the Food and Drug Administration for the treatment of patients with PNH in March 2007 (<a href="./references#CD010340-bbs2-0048" title="DmytrijukA , Robie‐SuhK , CohenMH , RievesD , WeissK , PazdurR . FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. The Oncologist2008;13(9):993‐1000. [PUBMED: 18784156] ">Dmytrijuk 2008</a>; <a href="./references#CD010340-bbs2-0049" title="DuboisEA , CohenAF . Eculizumab. British Journal of Clinical Pharmacology2009;68(3):318‐9. [PUBMED: 19740388] ">Dubois 2009</a>; <a href="./references#CD010340-bbs2-0128" title="ParkerCJ . The pathophysiology of paroxysmal nocturnal hemoglobinuria. Experimental Hematology2007;35(4):523‐33. [PUBMED: 17379062] ">Parker 2007</a>; <a href="./references#CD010340-bbs2-0130" title="ParkerC . Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet2009;373(9665):759‐67. [PUBMED: 19144399] ">Parker 2009b</a>). This drug was recommended for approval for the treatment of patients with PNH with a history of transfusions in the European Union in April 2007 (<a href="./references#CD010340-bbs2-0128" title="ParkerCJ . The pathophysiology of paroxysmal nocturnal hemoglobinuria. Experimental Hematology2007;35(4):523‐33. [PUBMED: 17379062] ">Parker 2007</a>). </p> </section> </section> </section> <section id="CD010340-sec-0039"> <h3 class="title" id="CD010340-sec-0039">How the intervention might work</h3> <p>Eculizumab is a humanized monoclonal antibody that binds specifically to complement protein C5 with high affinity, preventing its cleavage into C5a and C5b, thereby inhibiting complement‐mediated intravascular hemolysis in patients with PNH (<a href="./references#CD010340-bbs2-0088" title="HillA . Update on eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Clinical Advances in Hematology and Oncology2008;6(7):499‐500. [PUBMED: 18654116] ">Hill 2008</a>; <a href="./references#CD010340-bbs2-0089" title="HillA , RotherRP , ArnoldL , KellyR , CullenMJ , RichardsSJ , et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low‐level extravascular hemolysis occurring through C3 opsonization. Haematologica2010;95(4):567‐73. [PUBMED: 20145265] ">Hill 2010a</a>; <a href="./references#CD010340-bbs2-0116" title="McKeageK . Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs2011;71(17):2327‐45. [PUBMED: 22085388] ">McKeage 2011</a>; <a href="./references#CD010340-bbs2-0128" title="ParkerCJ . The pathophysiology of paroxysmal nocturnal hemoglobinuria. Experimental Hematology2007;35(4):523‐33. [PUBMED: 17379062] ">Parker 2007</a>; <a href="./references#CD010340-bbs2-0142" title="RisitanoAM , NotaroR , MarandoL , SerioB , RanaldiD , SenecaE , et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood2009;113(17):4094‐100. [PUBMED: 19179465] ">Risitano 2009</a>; <a href="./references#CD010340-bbs2-0143" title="RisitanoAM , PernaF , SelleriC . Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Reviews in Medicinal Chemistry2011;11(6):528‐35. [PUBMED: 21561403] ">Risitano 2011</a>; <a href="./references#CD010340-bbs2-0144" title="RisitanoAM . Paroxysmal nocturnal hemoglobinuria and other complement‐mediated hematological disorders. Immunobiology2012;217(11):1080‐7. [PUBMED: 22964233] ">Risitano 2012</a>; <a href="./references#CD010340-bbs2-0145" title="RisitanoAM . Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Advances in Experimental Medicine and Biology2013;734:155‐72. [PUBMED: 22990701] ">Risitano 2013</a>; <a href="./references#CD010340-bbs2-0176" title="WeitzIC , RazaviP , RochandaL , ZwickerJ , FurieB , ManlyD , et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thrombosis Research2012;130(3):361‐8. [PUBMED: 22542362] ">Weitz 2012</a>). C5 being common to all pathways of complement activation, its blockade effectively halts progression of the cascade regardless of the stimuli. Prevention of C5 cleavage also blocks the generation of the potent proinflammatory C5a and cell lytic molecules C5b‐9 (<a href="./references#CD010340-bbs2-0048" title="DmytrijukA , Robie‐SuhK , CohenMH , RievesD , WeissK , PazdurR . FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. The Oncologist2008;13(9):993‐1000. [PUBMED: 18784156] ">Dmytrijuk 2008</a>). While a dramatic decrease in intravascular hemolysis is found in most trials, many patients still have persistent anemia, reticulocytosis, and hemolysis which may be due to immune‐mediated extravascular hemolysis (<a href="./references#CD010340-bbs2-0089" title="HillA , RotherRP , ArnoldL , KellyR , CullenMJ , RichardsSJ , et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low‐level extravascular hemolysis occurring through C3 opsonization. Haematologica2010;95(4):567‐73. [PUBMED: 20145265] ">Hill 2010a</a>). The mechanism could be CD55‐deﬁcient PNH red cells becoming overloaded with C3 fragments because of inhibition of the terminal complement cascade steps by eculizumab (<a href="./references#CD010340-bbs2-0142" title="RisitanoAM , NotaroR , MarandoL , SerioB , RanaldiD , SenecaE , et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood2009;113(17):4094‐100. [PUBMED: 19179465] ">Risitano 2009</a>). However, this is a rare phenomenon and treatment with eculizumab has shown better hemolytic outcomes in terms of higher rates of hemoglobin stabilization, decreased need for transfusion, greater transfusion independence and an overall improvement in quality of life (<a href="./references#CD010340-bbs2-0048" title="DmytrijukA , Robie‐SuhK , CohenMH , RievesD , WeissK , PazdurR . FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. The Oncologist2008;13(9):993‐1000. [PUBMED: 18784156] ">Dmytrijuk 2008</a>; <a href="./references#CD010340-bbs2-0157" title="SchubertJ , HillmenP , RothA , YoungNS , ElebuteMO , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] ">Schubert 2008</a>; <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). </p> </section> <section id="CD010340-sec-0040"> <h3 class="title" id="CD010340-sec-0040">Why it is important to do this review</h3> <p>Controversy exists as to which patients suffering from PNH should be treated with this drug (<a href="./references#CD010340-bbs2-0079" title="HaspelRL , HillmenP . Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence‐based review 2008. Hematology2008:35. [PUBMED: 19074053] ">Haspel 2008</a>). Eculizumab therapy is associated with risk of infection by <i>Neisseria meningitidis</i> (<i>N. meningitidis</i>) (<a href="./references#CD010340-bbs2-0116" title="McKeageK . Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs2011;71(17):2327‐45. [PUBMED: 22085388] ">McKeage 2011</a>) and viral infections such as influenza or viral gastroenteritis (<a href="./references#CD010340-bbs2-0033" title="BrodskyRA , YoungNS , AntonioliE , RisitanoAM , SchrezenmeierH , SchubertJ , et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood2008;111(4):1840‐7. [PUBMED: 18055865] ">Brodsky 2008c</a>; <a href="./references#CD010340-bbs2-0034" title="BrodskyRA . How I treat paroxysmal nocturnal hemoglobinuria. Blood2009;113(26):6522‐7. [PUBMED: 19372253] ">Brodsky 2009a</a>; <a href="./references#CD010340-bbs2-0035" title="BrodskyRA . Paroxysmal nocturnal hemoglobinuria, Chapter 30. In: HoffmanR , FurieB , BenzEJ , McGlaveP , SilbersteinLE , ShattilSJ editor(s). Hematology: Basic Principles and Practice. 5th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2009:385‐94. ">Brodsky 2009b</a>). There is risk of <i>Neisseria meningitidis</i> (<i>N. meningitidis</i>) infection even after vaccination, and patients frequently require revaccination when on eculizumab treatment. Since eculizumab has no effect on the underlying cellular abnormality in PNH, treatment, once started, may require prolonged administration. This also raises economic concerns since eculizumab is an expensive drug (<a href="./references#CD010340-bbs2-0128" title="ParkerCJ . The pathophysiology of paroxysmal nocturnal hemoglobinuria. Experimental Hematology2007;35(4):523‐33. [PUBMED: 17379062] ">Parker 2007</a>). Thus, there is a need for a critical appraisal of RCTs to assess eculizumab in patients with PNH (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). This systematic review analyzing the available data might provide more definitive evidence regarding the role and safety of eculizumab in these patients. </p> <p>Eventually, this Cochrane review will help clinicians to make informed decisions on the use of eculizumab for treating patients with PNH. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010340-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010340-sec-0041"></div> <p>To assess the clinical benefits and harms of eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria (PNH), and to evaluate which patients might benefit most from its use. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010340-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010340-sec-0042"></div> <section id="CD010340-sec-0043"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010340-sec-0044"> <h4 class="title">Types of studies</h4> <p>According to the protocol of this review (<a href="./references#CD010340-bbs2-0114" title="Martí‐CarvajalAJ , AnandV , CardonaAF , SolàI . Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD010340] ">Martí‐Carvajal 2013</a>), we included RCTs irrespective of their publication status (trials may be unpublished or published as an article, an abstract, or a letter), language and country. We did not apply limits with respect to period of follow‐up. We excluded quasi‐RCTs. </p> </section> <section id="CD010340-sec-0045"> <h4 class="title">Types of participants</h4> <p>We included any patient with a confirmed diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) according to the International PNH interest group criteria (<a href="./references#CD010340-bbs2-0127" title="ParkerC , OmineM , RichardsS , NishimuraJ , BesslerM , WareR , et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood2005;106(12):3699‐709. [PUBMED: 16051736] ">Parker 2005</a>). We did not apply restrictions with respect to gender or ethnicity. </p> </section> <section id="CD010340-sec-0046"> <h4 class="title">Types of interventions</h4> <p>We planned the following two separate comparisons.</p> <p> <ol id="CD010340-list-0007"> <li> <p>Eculizumab versus placebo.</p> </li> <li> <p>Eculizumab versus other treatment: best available therapy.</p> </li> </ol> </p> <p>We only found one trial comparing eculizumab with placebo. For future updates we will continue to search for RCTs of eculizumab versus other treatment: best available therapy, or any other comparison. </p> </section> <section id="CD010340-sec-0047"> <h4 class="title">Types of outcome measures</h4> <section id="CD010340-sec-0048"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010340-list-0008"> <li> <p>Overall survival defined as the time from randomisation until death from any cause, and measured in the intent‐to‐treat population (<a href="./references#CD010340-bbs2-0055" title="Food , DrugAdministration . Clinical trial endpoints for the approval of cancer drugs and biologics. Guidance for Industry2007:1‐22. ">FDA 2007</a>). </p> </li> </ol> </p> </section> <section id="CD010340-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010340-list-0009"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Health‐related quality of life and fatigue assessed by a validated scale.</p> </li> <li> <p>Any fatal or nonfatal thrombotic event.</p> </li> <li> <p>Transformation to myelodysplastic syndrome and acute myelogenous leukemia.</p> </li> <li> <p>Adverse events (serious and nonserious). A serious adverse event, defined according to the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (<a href="./references#CD010340-bbs2-0095" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Media, PA: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>), is any untoward medical occurrence that at any dose results in death, is life‐threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. All other adverse events will be considered nonserious. </p> </li> <li> <p>Development and recurrence of aplastic anemia on treatment.</p> </li> <li> <p>Transfusion independence.</p> </li> <li> <p>Withdrawal for any reason.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010340-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>We developed the search strategy as indicated in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010340-bbs2-0109" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We conducted this process with the support of the Cochrane Haematological Malignancies Group (CHMG) Trials Search Co‐ordinator (TSC) and adjusted it for each database. </p> <section id="CD010340-sec-0051"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases.</p> <p> <ul id="CD010340-list-0010"> <li> <p><a href="http://www.thecochranelibrary.com/" target="_blank">The Cochrane Central Register of Controlled Trials</a> (CENTRAL, <i>The Cochrane Library</i> 2014, Issue 05). </p> </li> <li> <p><a href="http://ovidsp.tx.ovid.com/sp-3.8.1a/ovidweb.cgi?%26S=GCGMFPKKIDDDDBHDNCOKKEFBEIHIAA00%26New+Database=Single|8" target="_blank">MEDLINE (Ovid) and Ovid MEDLINE(R) In‐Process &amp; Other Non‐Indexed Citations</a> (from 1946 to 15 May 2014). </p> </li> <li> <p><a href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">PubMed</a> (up to May 2014). </p> </li> <li> <p><a href="http://www.elsevier.com/online-tools/embase" target="_blank">EMBASE</a> (OVID) (from 1980 to 25 June 2014). </p> </li> <li> <p><a href="http://lilacs.bvsalud.org/es/" target="_blank">LILACS</a> (from 1982 to 25 June 2014). </p> </li> </ul> </p> <p>See <a href="./appendices#CD010340-sec-0096">Appendix 2</a>; <a href="./appendices#CD010340-sec-0097">Appendix 3</a>; <a href="./appendices#CD010340-sec-0098">Appendix 4</a> ; <a href="./appendices#CD010340-sec-0099">Appendix 5</a>; <a href="./appendices#CD010340-sec-0100">Appendix 6</a> for details. </p> </section> <section id="CD010340-sec-0052"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD010340-list-0011"> <li> <p>We searched the following trial databases for ongoing and unpublished trials on June 2014. </p> </li> </ul> <ol id="CD010340-list-0012"> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">The Clinical Trials Search Portal of the World Health Organization (WHO)</a> </p> </li> <li> <p><a href="http:////www.controlled-trials.com/mrct/" target="_blank">The Metaregister of Controlled Trials</a> </p> </li> <li> <p><a href="http://clincalstrials.gov/" target="_blank">ClinicalTrials.gov</a>  </p> </li> </ol> <ul id="CD010340-list-0013"> <li> <p>We searched the following conference proceedings from 2000 to December 2012, (if they were not included in CENTRAL). </p> </li> </ul> <ol id="CD010340-list-0014"> <li> <p><a href="http://www.hematology.org" target="_blank">American Society of Hematology (ASH)</a>: <i>Blood</i> (Volume 104(11) 2004; 106(11) 2005; 108(11) 2006; 110(11) 2007; 112(11) 2008; 114(22) 2009; 116(21) 2010; 118(21) 2011; 120(21) 2012). </p> </li> <li> <p><a href="http://ehaweb.org" target="_blank">European Hematology Association (EHA)</a>: <i>Haematologica</i> (Vol 91 2006; 92 2007; 93 2008; 94 2009; 95 2010; 96 2011; 97 2012). </p> </li> <li> <p><a href="http://www.asco.org" target="_blank">American Society for Clinical Oncology (ASCO)</a>: <i>Journal Clinical Oncology</i> (Vol 22(14S) 2004; 23(16S) 2005; 24(18S) 2006; 25(18S) 2007; 26 (15S) 2008; 27(15S) 2009; 27(18S) 2009; 28(15) 2010; 28(18) 2010; 29(15) and (18) 2011; 30(15) and (18) 2012). </p> </li> <li> <p><a href="http://esmo.org/" target="_blank">European Society of Medical Oncology (ESMO)</a>: <i>Annals of Oncology</i> (Volumen 15 (Suppl 3) (Suppl 4) 2004; 16 (Suppl 2), 2005; 17 (Suppl 9) and (Suppl 10) 2006; 18 (Suppl 9) 2007; 19(Suppl 7) and (Suppl 8) 2008; 21 (Suppl 7) and (Suppl 8) 2010; 23 (Suppl 9) and (Suppl 10) 2012). </p> </li> </ol> <ul id="CD010340-list-0015"> <li> <p>We also searched the following websites on June 2014.</p> </li> </ul> <ol id="CD010340-list-0016"> <li> <p><a href="http://www.fda.gov" target="_blank">Food and Drug Administration</a> </p> </li> <li> <p><a href="http://www.ema.europa.eu/" target="_blank">European Medicines Agency</a> </p> </li> <li> <p><a href="http://www.epistemonikos.org/" target="_blank">www.epistemonikos.org/</a> </p> </li> </ol> </p> <p>We handsearched the references of all identified included trials, of relevant review articles and of current treatment guidelines. We also contacted the authors from included trials to identify unpublished trials. We did not apply any language restrictions. </p> </section> </section> <section id="CD010340-sec-0053"> <h3 class="title" id="CD010340-sec-0053">Data collection and analysis</h3> <p>We summarized data using standard Cochrane Collaboration methodologies (<a href="./references#CD010340-bbs2-0083" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> <section id="CD010340-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Methods for study selection followed the steps delineated by the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010340-bbs2-0083" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> <p>AMC, VA and AFC screened the titles and abstracts identified from the above sources to identify potential studies for inclusion. If this could not be done satisfactorily from the title and abstract, we sought a full text version for assessment. We presented the results of the study selection according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement (<a href="./references#CD010340-bbs2-0120" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>). See <a href="#CD010340-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010340-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010340-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We resolved any disagreement through discussion and consensus, or if required, we consulted Ivan Solà. </p> </section> <section id="CD010340-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>We used a form to extract data. Overall, we extracted and filled in the following data: review, review author and study information, eligibility criteria, characteristics of the participants (age, gender, country), trial design and funding, related variables, intervention duration and dosage, outcomes. We extracted quality criteria according to risk of bias using the Cochrane Collaboration’s tool for assessing risk of bias: random sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective reporting; and other bias (<a href="./references#CD010340-bbs2-0083" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> <p>For each eligible trial, AMC and VA extracted the data using the agreed form in duplicate. We resolved discrepancies through discussion or, if required, we consulted AFC and IS. </p> <p>AMC and VA entered data into Review Manager software (<a href="./references#CD010340-bbs2-0140" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and IS checked it for accuracy. </p> </section> <section id="CD010340-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>AMC and VA and IS in pairs, independently assessed the risk of bias of each trial using a simple form, and followed the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010340-bbs2-0084" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). We resolved any discrepancies through discussion or consultation with AFC. </p> <p>We assessed the following domains as 'low risk of bias', 'unclear' or 'high risk of bias'. </p> <p> <ol id="CD010340-list-0017"> <li> <p>Generation of allocation sequence.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessors.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting.</p> </li> <li> <p>Other sources of bias.</p> </li> </ol> </p> <section id="CD010340-sec-0057"> <h5 class="title">Overall risk of bias</h5> <p>We considered low risk of bias trials to be those that adequately generated their allocation sequence; had adequate allocation concealment, adequate blinding, adequate handling of incomplete outcome data; were free of selective outcome reporting; and were free of other bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010340-bbs2-0084" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). As it was unlikely that we would find many trials at low risk of bias in all items, we chose three core domains instead of all: generation of allocation sequence, incomplete outcome data, and selective reporting bias. </p> </section> </section> <section id="CD010340-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>For the following binary outcomes, we would have calculated the relative risk (RR) with 95% confidence intervals (CI): </p> <p> <ol id="CD010340-list-0018"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Any fatal or nonfatal thrombotic event.</p> </li> <li> <p>Adverse events (serious and nonserious).</p> </li> <li> <p>Transformation to myelodysplastic syndrome and acute myelogenous leukemia.</p> </li> <li> <p>Development, and recurrence of aplastic anemia on treatment.</p> </li> <li> <p>Transfusion independence.</p> </li> <li> <p>Withdrawal due to any reason.</p> </li> </ol> </p> <p>For continuous outcomes (health‐related quality of life and fatigue assessed by a validated scale), we would have calculated the standardized mean difference with 95% CI. </p> <p>For time‐to‐event outcomes (overall survival), we would have calculated the hazard ratio for each outcome with 95% CI. </p> </section> <section id="CD010340-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>We would have used the following procedures (and will apply these for future updates, if possible). We would have noted levels of attrition and explored the impact of high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.<br/> For all outcomes we would have carried out analysis, as far as possible, on an intention‐to‐treat basis (i.e. we would have attempted to include all participants randomized to each group in the analyses). The denominator for each outcome in each trial would have been the number randomized minus any participants whose outcomes are known to be missing (<a href="./references#CD010340-bbs2-0084" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD010340-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>We did not conduct a meta‐analysis because we identified only one RCT. In future updates, we will assess statistical heterogeneity in each meta‐analysis using the T², I² and Chi² statistics. We will regard heterogeneity as substantial if I² is greater than 30% and either T² is greater than zero, or there is a low P value (less than 0.10) in the Chi² test for heterogeneity. We will investigate possible causes of heterogeneity through subgroup analysis (<a href="./references#CD010340-bbs2-0047" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD010340-sec-0061"> <h4 class="title">Assessment of reporting biases</h4> <p>We would have used the following procedures for reporting bias (and will apply these for future updates, if possible). We would have attempted to assess whether the review was subjected to publication bias by using a funnel plot to illustrate variability graphically between trials. We would have assessed publication bias if at least 10 trials were available so that it was possible to make judgments about asymmetry, and if asymmetry was present, we would have explored causes other than publication bias (<a href="./references#CD010340-bbs2-0161" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. [PUBMED: 21784880] ">Sterne 2011</a>). </p> </section> <section id="CD010340-sec-0062"> <h4 class="title">Data synthesis</h4> <p>We would have used the following procedures (and will apply these for future updates, if possible). We would have carried out statistical analysis using Review Manager software (<a href="./references#CD010340-bbs2-0140" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). If the eligible trials were sufficiently comparable in their clinical characteristics, we would have summarized their findings using a random‐effects model according to the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> section 9.4 (<a href="./references#CD010340-bbs2-0047" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). If the I<sup>2</sup> statistic had been greater than 0, we would have reported the results from both random‐effects and fixed‐effect models. </p> <section id="CD010340-sec-0063"> <h5 class="title">'Summary of findings' table</h5> <p>We used the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group (<a href="./references#CD010340-bbs2-0065" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence‐imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. [PUBMED: 21839614] ">Guyatt 2011a</a>) to assess the quality of the body of evidence associated with up to seven outcomes. We constructed a 'Summary of findings' table using the GRADE profiler software (<a href="./references#CD010340-bbs2-0061" title="GRADE Working Group. GRADEpro. Version 3.2 for Windows. McMaster University, 2008. ">GRADEpro 2008</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Evaluation of the quality of a body of evidence considers within‐study risk of bias, the directness of the evidence, heterogeneity in the data, precision of effect estimates and risk of publication bias (<a href="./references#CD010340-bbs2-0025" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [PUBMED: 21208779] ">Balshem 2011</a>; <a href="./references#CD010340-bbs2-0037" title="BrozekJL , AklEA , CompalatiE , KreisJ , TerraccianoL , FiocchiA , et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy2011;66(5):588‐95. [PUBMED: 21241318] ">Brozek 2011</a>; <a href="./references#CD010340-bbs2-0066" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence‐inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [PUBMED: 21803546] ">Guyatt 2011b</a>; <a href="./references#CD010340-bbs2-0067" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence‐publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011c</a>; <a href="./references#CD010340-bbs2-0068" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence‐indirectness. Journal of Clinical Epidemiology2011;64(12):1303‐10. [PUBMED: 21802903] ">Guyatt 2011d</a>; <a href="./references#CD010340-bbs2-0069" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. [PUBMED: 21802902] ">Guyatt 2011e</a>; <a href="./references#CD010340-bbs2-0070" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence‐study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407‐15. [PUBMED: 21247734] ">Guyatt 2011f</a>; <a href="./references#CD010340-bbs2-0071" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011g</a>; <a href="./references#CD010340-bbs2-0072" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. [PUBMED: 21194891] ">Guyatt 2011h</a>; <a href="./references#CD010340-bbs2-0073" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380‐2. [PUBMED: 21185693] ">Guyatt 2011i</a>; <a href="./references#CD010340-bbs2-0074" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence‐publication bias. Journal of Clinical Epidemiology2011;64(12):1277‐82. [PUBMED: 21802904] ">Guyatt 2011j</a>; <a href="./references#CD010340-bbs2-0075" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines 11‐making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151‐7. [PUBMED: 22542023] ">Guyatt 2012</a>). Due to the inclusion of a unique study in the review, we reported in the 'Summary of findings' table the outcomes that reported the included trial. We maintained the most patient important outcomes planned at the protocol stage (see <a href="#CD010340-sec-0106">Differences between protocol and review</a> section), and added fatigue, transfusion independence, and withdrawal for any reason. Although <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> did not assess overall survival, we included this outcome because it is the primary outcome of this Cochrane review. </p> </section> </section> <section id="CD010340-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We will use the following procedures, and will apply these for future updates, if possible. We will devote further efforts to identifying possible causes of heterogeneity. We will explore the impact of the included trials' risk of bias and the condition of the individuals by subgroup analyses. We anticipate clinical heterogeneity for the following participant and intervention characteristics. </p> <p> <ol id="CD010340-list-0019"> <li> <p>Age.</p> </li> <li> <p>Duration of follow‐up.</p> </li> <li> <p>Type of PNH: classical, subclinical or associated with other bone marrow disorders.</p> </li> <li> <p>Aplastic anemia.</p> </li> <li> <p>Thrombotic episodes.</p> </li> <li> <p>PIGA mutation status at screening.</p> </li> <li> <p>Previous PNH therapy including dose and duration of therapy.</p> </li> </ol> </p> <p>These different variables will justify subgroup analyses. We will perform subgroup analysis only for primary outcomes. </p> </section> <section id="CD010340-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We will use the following procedures for future updates, if possible. We will conduct sensitivity analyses according to the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> section 9.4 (<a href="./references#CD010340-bbs2-0047" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> <p>If sufficient trials are identified, we will conduct a sensitivity analysis excluding the following. </p> <p> <ol id="CD010340-list-0020"> <li> <p>Those RCTs at a high risk of bias (see <a href="#CD010340-sec-0056">Assessment of risk of bias in included studies</a>). Trials at high risk of bias would not have been removed from the main analysis but would be analyzed separately. </p> </li> <li> <p>Those RCTs with a total attrition of more than 30%, or where baseline differences between the groups exceed 10%, or both. </p> </li> </ol> </p> <p>We will conduct a trial sequential analysis (TSA), which is a methodology that combines an information size calculation (cumulated sample sizes of included trials) for meta‐analysis with the threshold of statistical significance. TSA is a tool for quantifying the statistical reliability of data in a cumulative meta‐analysis adjusting P values for repetitive testing on accumulating data. We will conduct a TSA on binary and continuous outcomes (<a href="./references#CD010340-bbs2-0036" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive: trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD010340-bbs2-0134" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93; discussion 661‐6. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD010340-bbs2-0135" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):47‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD010340-bbs2-0164" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology2009;38(1):276‐86. [PUBMED: 18824467] ">Thorlund 2009</a>; <a href="./references#CD010340-bbs2-0177" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD010340-bbs2-0178" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>) in future updates, if applicable. Meta‐analysis may result in type I errors due to sparse data or due to repeated significance testing when updating meta‐analysis with new trials (<a href="./references#CD010340-bbs2-0036" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive: trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD010340-bbs2-0085" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21472757] ">Higgins 2011c</a>; <a href="./references#CD010340-bbs2-0177" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). In a single trial, interim analysis increases the risk of type I errors. To avoid type I errors, group sequential monitoring boundaries are applied to decide whether a trial could be terminated early because of a sufficiently small P value, that is, the cumulative Z‐curve crosses the monitoring boundaries (<a href="./references#CD010340-bbs2-0107" title="LanGKK , DemetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70(3):659‐63. ">Lan 1983</a>). Sequential monitoring boundaries can be applied to meta‐analysis as well, called trial sequential monitoring boundaries (<a href="./references#CD010340-bbs2-0177" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD010340-bbs2-0178" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [PUBMED: 20042080] ">Wetterslev 2009</a>). In TSA, the addition of each trial in a cumulative meta‐analysis is regarded as an interim meta‐analysis and helps to clarify whether additional trials are needed. The idea in TSA is that if the cumulative Z‐curve crosses the boundary, a sufficient level of evidence is reached and no further trials may be needed. If the Z‐curve does not cross the boundary then there is insufficient evidence to reach a conclusion. To construct the trial sequential monitoring boundaries, the required information size is needed, and is calculated as the least number of participants needed in a well‐powered single trial (<a href="./references#CD010340-bbs2-0036" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive: trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD010340-bbs2-0134" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93; discussion 661‐6. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD010340-bbs2-0135" title="PogueJ , YusufS . Overcoming the limitations of current meta‐analysis of randomised controlled trials. Lancet1998;351(9095):47‐52. [PUBMED: 9433436] ">Pogue 1998</a>; <a href="./references#CD010340-bbs2-0177" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). We will apply TSA since it prevents an increase of the risk of type I error (&lt; 5%) due to potential multiple updating in a cumulative meta‐analysis, and provides us with important information in order to estimate the level of evidence of the experimental intervention. </p> <p>Additionally, TSA will provide us with important information regarding the need for additional trials and the required sample size of such trials. We will apply trial sequential monitoring boundaries according to a heterogeneity‐adjusted required information size based on an a priori 10% relative risk reduction (employing α = 0.05 and ß = 0.20. </p> <p>We will conduct TSA using the TSA software (<a href="./references#CD010340-bbs2-0044" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Copenhagen: Copenhagen Trial Unit, 2011. ">CTU 2011</a>; <a href="./references#CD010340-bbs2-0165" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf (accessed 30 April 2012). ">Thorlund 2011</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010340-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010340-sec-0066"></div> <section id="CD010340-sec-0067"> <h3 class="title">Description of studies</h3> <section id="CD010340-sec-0068"> <h4 class="title">Results of the search</h4> <p>We retrieved 3987 references from electronic searches, and 174 through other sources. After removing duplicates, we screened 4161 unique references for eligibility. The revision of title and abstracts led to the exclusion of 4133 references, and the obtainment of 28 publications for their review in detail. We excluded 14 of these publications. The rest of these publications were related to a unique trial (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). <a href="#CD010340-fig-0001">Figure 1</a> shows a flowchart of the study selection following PRISMA guidance (<a href="./references#CD010340-bbs2-0120" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [PUBMED: 19631508] ">Moher 2009</a>). </p> </section> <section id="CD010340-sec-0069"> <h4 class="title">Included studies</h4> <p>The included trial compared eculizumab (infusions of 600 mg every week for four weeks, followed one week later by 900 mg, and then by a maintenance dose of 900 mg every two weeks) with placebo. This trial included 87 participants and the median age of the participants was 41 years (range: 20 to 85). Over 50% (52/87) of the participants were female. The trial was conducted in 34 sites in Europe, Australia, Canada and the US from October 2004 to June 2005. The trial was conducted using the parallel trial design and had a follow‐up of 26 weeks (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). </p> <p>The <a href="./references#CD010340-sec-0108" title="">Characteristics of included studies</a> table shows a detailed description of the <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>. </p> </section> <section id="CD010340-sec-0070"> <h4 class="title">Excluded studies</h4> <p>Fourteen publications were excluded for the following reasons: case series studies (<a href="./references#CD010340-bbs2-0003" title="ArnoldLM , BrooksbankGL , KellyRJ , HillA , RichardsSJ , SeniorR , et al. Continued benefit from prolonged treatment with eculizumab in 130 patients with PNH in the UK: home delivery of eculizumab is safe, convenient and associated with very high levels of patient satisfaction. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118:4368. ArnoldLM , StephensonJ , KellyR , BuchananD , JonesG , HillmenP . Home infusion of eculizumab: a unique and innovative model of drug delivery to reduce treatment‐associated burden and enhance quality of life for patients with PNH. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4671. ">Arnold 2008</a>; <a href="./references#CD010340-bbs2-0004" title="BrodskyRA , deCastroC , SchrezenmeierH , RisitanoAM , SchubertJ , MaciejewskiJP , et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2010; Vol. 116:4237. ">Brodsky 2010</a>; <a href="./references#CD010340-bbs2-0005" title="HillA , KellyRJ , KulasekararajAG , GandhiSA , MitchellLD , ElebuteM , et al. Eculizumab in paroxysmal nocturnal hemoglobinuria (PNH): A report of all 153 patients treated in the UK. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120:3472. ">Hill 2012</a>; <a href="./references#CD010340-bbs2-0006" title="HillmenP , MuusP , DührsenU , RisitanoAM , SchubertJ , YoungNS . The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:123. ">Hillmen 2006</a>; <a href="./references#CD010340-bbs2-0007" title="HöchsmannB , LeichtleR , vonZabernI , KaiserS , FlegelWA , SchrezenmeierH . Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test. Vox Sanguinis2012;102(2):159‐66. [PUBMED: 21929681] ">Höchsmann 2012</a>; <a href="./references#CD010340-bbs2-0009" title="KellyRJ , HillA , ArnoldLM , BrooksbankGL , RichardsSJ , CullenM , et al. Long‐term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood2011;117(25):6786‐92. [PUBMED: 21460245] ">Kelly 2011</a>; <a href="./references#CD010340-bbs2-0010" title="KimJS , LeeJW , KimBK , LeeJH , ChungJ . The use of the complement inhibitor eculizumab (Soliris(R)) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. The Korean Journal of Hematology2010;45(4):269‐74. [PUBMED: 21253430] ">Kim 2010</a>; <a href="./references#CD010340-bbs2-0011" title="Lopez RubioM , MoradoM , GayaA , Alonso RosaD , OjedaE , MunozJA , et al. [Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience] [Tratamiento de la hemoglobinuria paroxística nocturna con eculizumab: experiencia en España]. Medicina Clínica2011;137(1):8‐13. [PUBMED: 21296371] ">Lopez 2011</a>; <a href="./references#CD010340-bbs2-0012" title="ReissUM , SchwartzJ , SakamotoKM , PuthenveetilG , OgawaM , WareRE , et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118:1034. ">Reiss 2011</a>; <a href="./references#CD010340-bbs2-0015" title="SzerJ , MuusP , RoethA , ElebuteMO , RisitanoA , SchrezenmeierH , et al. Long‐term safety of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria. Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 1260. 2012. ">Szer 2012</a>); controlled or noncontrolled trials (<a href="./references#CD010340-bbs2-0002" title="KanakuraY , OhyashikiK , ShichishimaT , OkamotoS , AndoK , NinomiyaH . Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: AEGIS phase II clinical study results. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:3438. KanakuraY , OhyashikiK , ShichishimaT , OkamotoS , AndoK , NinomiyaH , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. International Journal of Hematology2011;93(1):36‐46. [PUBMED: 21222185] ">AEGIS 2008</a>; <a href="./references#CD010340-bbs2-0014" title="BrodskyRA , YoungNS , AntonioliE , RisitanoAM , SchrezenmeierH , SchubertJ , et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood2008;111(4):1840‐7. [PUBMED: 18055865] SchrezenmeierH , LuzzattoL , RotoliB , YoungNS , SchubertJ , Urbano‐IspizuaA . Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: SHEPHERD phase III clinical study results. Haematologica2007; Vol. 92, issue Suppl 1. [CN‐00646861] YoungNS , AntonioliE , RotoliB , SchrezenmeierH , SchubertJ , Urbano‐IspizuaA . Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: interim SHEPHERD phase III clinical study. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:971. ">SHEPHERD 2008</a>);case report (<a href="./references#CD010340-bbs2-0008" title="JohnS , ParekhHD , QubaiahOM , SelbyGS , HolterJL . Hypoplastic MDS with PNH clone treated successfully with eculizumab. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30:e17010. ">John 2012</a>); and pooled analysis of two studies (<a href="./references#CD010340-bbs2-0013" title="SchubertJ , HillmenP , RothA , YoungNS , ElebuteMO , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] ">Schubert 2008a</a>). See <a href="./references#CD010340-sec-0109" title="">Characteristics of excluded studies</a> table. </p> <section id="CD010340-sec-0071"> <h5 class="title">Multiple and duplicate publications</h5> <p><a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> is associated with 14 publications. </p> </section> <section id="CD010340-sec-0072"> <h5 class="title">Ongoing studies</h5> <p>We found two ongoing RCTs (<a href="./references#CD010340-bbs2-0016" title="Eculizumab to treat paroxysmal nocturnal hemoglobinuria. Ongoing studyDecember 2004. ">NCT00098280</a>; <a href="./references#CD010340-bbs2-0017" title="Eculizumab in treating patients with paroxysmal nocturnal hemoglobinuria. Ongoing studyNovember 2004. ">NCT00112983</a>). Both ongoing trials are subsets of randomized trial records such as is reported in <a href="http://www.controlled-trials.com/mrct/search.html" target="_blank">The Metaregister of Controlled Trials</a> and <a href="http://clincalstrials.gov/" target="_blank">ClinicalTrials.gov</a> (accessed on 25 June 2014). These trials have been reported as completed. See <a href="./references#CD010340-sec-0110" title="">Characteristics of ongoing studies</a> for details. </p> </section> </section> </section> <section id="CD010340-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of the included trial (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>) is summarized in <a href="#CD010340-fig-0002">Figure 2</a> and <a href="#CD010340-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010340-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010340-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010340-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010340-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010340-sec-0074"> <h4 class="title">Allocation</h4> <p>Randomization was performed centrally by means of an interactive voice–response system. Therefore, we considered the risk of bias arising from the method of generation of the allocation sequence and allocation concealment to be low (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). </p> </section> <section id="CD010340-sec-0075"> <h4 class="title">Blinding</h4> <p><a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> was reported as a double‐blind trial. However, the method of blinding was not described to guarantee an appropriate masking. Therefore, we rated the risk of bias arising from lack of blinding of participants and personnel as unclear (<a href="./references#CD010340-bbs2-0180" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [PUBMED: 18316340] ">Wood 2008</a>). </p> <p>We rated the risk of bias arising from lack of blinding of outcome assessment as low for adverse events (serious and nonserious), patients with transfusion independence, and withdrawal for any reason, because these are objective endpoints. </p> <p>We rated the risk of bias arising from lack of blinding of outcome assessment as unclear for health‐related quality of life and fatigue as the method of blinding described did not guarantee an appropriate masking (<a href="./references#CD010340-bbs2-0180" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [PUBMED: 18316340] ">Wood 2008</a>). </p> </section> <section id="CD010340-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>, 14% of participants dropped out and there was an imbalance between groups of 18%. The eculizumab group lost 5% (2/43) due to pregnancy, and the research center being a long distance from participants’ homes. In contrast, the placebo group lost 23% (10/44) because the participants perceived a lack of efficacy. In conclusion, we rated the risk of attrition bias as high. </p> </section> <section id="CD010340-sec-0077"> <h4 class="title">Selective reporting</h4> <p>We rated risk of reporting bias as high because <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> did not assess one or more clinically relevant and reasonably expected outcomes, and data on these outcomes were likely to have been recorded. This trial did not report information on transformation to myelodysplastic syndrome and acute myelogenous leukemia, and development and recurrence of aplastic anemia. </p> </section> <section id="CD010340-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>We did not detect any other potential sources of bias.</p> </section> </section> <section id="CD010340-sec-0079"> <h3 class="title" id="CD010340-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD010340-tbl-0001"><b>Summary of findings for the main comparison</b> Eculizumab compared with placebo for paroxysmal nocturnal hemoglobinuria</a> </p> <p>The results are based on one trial involving 87 participants (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). See <a href="./full#CD010340-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD010340-sec-0080"> <h4 class="title">Primary outcomes</h4> <section id="CD010340-sec-0081"> <h5 class="title">Overall survival</h5> <p>The included study did not assess this outcome, but the main publication reported that no patients died during the study (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). </p> </section> </section> <section id="CD010340-sec-0082"> <h4 class="title">Secondary outcomes</h4> <p><a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> reported on only five of our outcomes of interest. No data were available on the other outcomes (transformation to myelodysplastic syndrome and acute myelogenous leukemia, and development and recurrence of aplastic anemia on treatment).   </p> <p><b>All‐cause mortality</b> </p> <p>No patients died during the execution of the included trial.</p> <p><b>Health‐related quality of life and fatigue</b> </p> <p>The assessment of health‐related quality of life was based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (scores can range from 0 to 100, with higher scores on the global health status and functioning scales and lower scores on the symptom scales and single‐item measures indicating improvement). Among the 87 participants, there was a statistically and clinically significant increase in the global health status scale in the eculizumab group compared with the placebo group (mean difference (MD) 19.4, 95% confidence interval (CI) 8.25 to 30.55; P = 0.0007) (<a href="./references#CD010340-fig-0004" title="">Analysis 1.1</a>). </p> <p>The assessment of fatigue was based on the Functional Assessment of Chronic Illness Therapy Fatigue instrument (scores can range from 0 to 52, with higher scores indicating improvement in fatigue). A change of three or more points in scores on this instrument represents a clinically important difference. The 43 participants into eculizumab group showed a statistical and clinical significant reduction in fatigue compared with the 44 participants of the placebo group (MD 10.4, 95% CI 9.97 to 10.83; P = 0.00001) (<a href="./references#CD010340-fig-0005" title="">Analysis 1.2</a>). </p> <p><b>Any fatal or nonfatal thrombotic event</b> </p> <p>Over the course of the trial, an episode of thrombosis occurred in the placebo group. This event was considered a single thrombosis (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> reported a low rate of serious adverse effects that resulted in a nonsignificant statistical difference between the eculizumab group: 9.3% (4/43) versus the placebo group: 20.4% (9/44) (RR 0.45, 95% CI 0.15 to 1.37; P = 0.16, 87 participants). There was a nonsignificant statistical difference according to specific serious adverse events (<a href="./references#CD010340-fig-0006" title="">Analysis 1.3</a>). </p> <p>There was a nonsignificant statistical difference according to the most frequent adverse events (Headache, nasopharyngitis, upper respiratory tract infection, back pain, and nausea) (<a href="./references#CD010340-fig-0007" title="">Analysis 1.4</a>). </p> <p><b>Transfusion independence</b> </p> <p><a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> reported 22 out of 43 participants with transfusion independence in the eculizumab group (51% (22/43)) and none in the placebo group (RR 46.02, 95% CI 2.88 to 735.53; P = 0.007) (<a href="./references#CD010340-fig-0008" title="">Analysis 1.5</a>). </p> <p><b>Withdrawal for any reason</b> </p> <p><a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> reported a statistical significant reduction of withdrawal for any reason in the eculizumab arm (4.7% (2/43) compared with the placebo group (22.7% (10/44)) (RR 0.20, 95% CI 0.05 to 0.88; P = 0.03) (<a href="./references#CD010340-fig-0009" title="">Analysis 1.6</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010340-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010340-sec-0083"></div> <section id="CD010340-sec-0084"> <h3 class="title" id="CD010340-sec-0084">Summary of main results</h3> <p>Our aim was to assess the influence of eculizumab on the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). This Cochrane review found one sponsored drug company trial with 26 weeks of follow‐up, comparing eculizumab against placebo, involving 87 patients (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). Eculizumab improved health‐related quality of life, showed a higher proportion of patients with transfusion independence, and reduced fatigue and withdrawal for any reason. The administration of eculizumab did not affect the occurrence of adverse events (serious or not serious). No patients died during the trial, and one case of thrombosis was reported in the placebo group. The trial did not assess overall survival, any fatal or nonfatal thrombotic event, transformation to myelodysplastic syndrome and acute myelogenous leukemia, and development and recurrence of aplastic anemia on treatment. See <a href="./full#CD010340-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD010340-sec-0085"> <h3 class="title" id="CD010340-sec-0085">Overall completeness and applicability of evidence</h3> <p>PNH is classified into three categories (<a href="./references#CD010340-bbs2-0132" title="ParkerCJ . Paroxysmal nocturnal hemoglobinuria. Current Opinion in Hematology2012;19(3):141‐8. [PUBMED: 22395662] ">Parker 2012</a>). The included trial involved only classic PNH (<a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a>). It was conducted with fewer than 100 patients, and rated as high or unclear risk of bias in many domains. Therefore, three issues emerge. First, external validity is restricted to patients with classic PNH. Second, a low number of participants carry a risk of random error (play of chance). It is also known as type I error (alpha error) and type II error (beta error) (<a href="./references#CD010340-bbs2-0136" title="PortaM . A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008. ">Porta 2008</a>). Type I error (alpha error) is the error of wrongly rejecting a null hypothesis, i.e. declaring that a difference exists when it does not (<a href="./references#CD010340-bbs2-0136" title="PortaM . A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008. ">Porta 2008</a>). Type II error (beta error) is the error of failing to reject a false null hypothesis, i.e. declaring that a difference does not exist, when in fact it does (<a href="./references#CD010340-bbs2-0136" title="PortaM . A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008. ">Porta 2008</a>). Third, <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> had a high risk of systematic errors (bias, that is, overestimation of benefits ‐ positive false result ‐ and underestimation of harms ‐ negative false result) (<a href="./references#CD010340-bbs2-0038" title="ButtonKS , IoannidisJP , MokryszC , NosekBA , FlintJ , RobinsonES , et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews. Neuroscience2013;14(5):365‐76. [PUBMED: 23571845] ">Button 2013</a>; <a href="./references#CD010340-bbs2-0105" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [PUBMED: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD010340-bbs2-0151" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012</a>; <a href="./references#CD010340-bbs2-0152" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment2012;16(35):1‐82. [PUBMED: 22989478] ">Savović 2012a</a>; <a href="./references#CD010340-bbs2-0166" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐a simulation study. PloS One2011;6(10):e25491. [PUBMED: 22028777] ">Thorlund 2011a</a>). Thus, overall completeness and applicability of evidence is poor due to potential spurious findings. </p> <p>Three additional issues can reduce the applicability of the evidence: selective outcome reporting, incomplete outcome data issues, and unblinding for the outcome assessment of quality of life and fatigue. These issues may be particularly relevant to consider as a further trial is planned. <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> did not report the main clinical outcomes. Trials should adopt an agreed upon set of core outcomes for each medical condition (<a href="./references#CD010340-bbs2-0043" title="ClarkeM . Standardising outcomes for clinical trials and systematic reviews. Trials2007;8:39. [PUBMED: 18039365] ">Clarke 2007</a>). This approach may reduce the impact of outcome reporting bias (<a href="./references#CD010340-bbs2-0104" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. ">Kirkham 2010</a>). The impact of outcome reporting bias may be reduced for adopting the recommendations of The Patient‐Centered Outcomes Research Institute (PCORI) (<a href="./references#CD010340-bbs2-0133" title="Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: “Our questions, our decisions: Standards for patient‐centered outcomes research”. http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 18 February 2013). ">PCORI 2012</a>). PCORI's research is intended to give patients a better understanding of the prevention, treatment and care options available, and the science that supports those options (<a href="./references#CD010340-bbs2-0027" title="BaschE , AronsonN , BergA , FlumD , GabrielS , GoodmanSN , et al. Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA2012;307(15):1636‐40. [PUBMED: 22511692] ">Basch 2012</a>; <a href="./references#CD010340-bbs2-0058" title="GabrielSE , NormandSL . Getting the Methods Right ‐ The Foundation of Patient‐Centered Outcomes Research. The New England Journal of Medicine2012;367(9):787‐90. [PUBMED: 22830434] ">Gabriel 2012</a>; <a href="./references#CD010340-bbs2-0133" title="Patient‐Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: “Our questions, our decisions: Standards for patient‐centered outcomes research”. http://www.pcori.org/assets/Preliminary‐Draft‐Methodology‐Report.pdf (accessed 18 February 2013). ">PCORI 2012</a>). Eculizumab is an expensive drug (<a href="./references#CD010340-bbs2-0128" title="ParkerCJ . The pathophysiology of paroxysmal nocturnal hemoglobinuria. Experimental Hematology2007;35(4):523‐33. [PUBMED: 17379062] ">Parker 2007</a>). Therefore, the outcomes should take into account the financial aspects. <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> was analyzed using an intention to treat analysis approach, however, the trial had a high risk of attrition bias which acts as selection bias. Finally, lack of blinding for the outcome assessment of quality of life and fatigue reduce the reliability of the evidence (<a href="./references#CD010340-bbs2-0151" title="SavovićJ , JonesH , AltmanD , HarrisR , JűniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savović 2012</a>; <a href="./references#CD010340-bbs2-0180" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [PUBMED: 18316340] ">Wood 2008</a>). </p> </section> <section id="CD010340-sec-0086"> <h3 class="title" id="CD010340-sec-0086">Quality of the evidence</h3> <p>We rated the quality of evidence for the relevant outcomes of the review (see <a href="./full#CD010340-tbl-0001">summary of findings Table for the main comparison</a>). The quality of evidence for eculizumab in patients with PNH is moderate to low due to limitations in the design and execution of the included trial, and imprecision in some effect estimates. The unblinded outcome assessment and the high attrition due to the perceived lack of efficacy within the patients that received placebo in the TRIUMPH trial could bias the differences observed in quality of life and fatigue scores. For quality of life we also downgraded the quality of evidence for the imprecision of the effect estimate, suggesting the possibility of a moderate to important effect in the EORTC QLQ‐C30 scores. Instead, the effect estimates and the values in the confidence interval for fatigue are included between those established in the literature as minimally important differences (<a href="./references#CD010340-bbs2-0039" title="CellaD , EtonDT , LaiJS , PetermanAH , MerkelDE . Combining anchor and distribution‐based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management2002;24(6):547‐61. [PUBMED: 12551804] ">Cella 2002</a>; <a href="./references#CD010340-bbs2-0175" title="WebsterK , CellaD , YostK . The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health and Quality of Life Outcomes2003;1:79. [PUBMED: 14678568] ">Webster 2003</a>). We downgraded the quality of evidence for the low rate of events reported for the rest of the outcomes. </p> </section> <section id="CD010340-sec-0087"> <h3 class="title" id="CD010340-sec-0087">Potential biases in the review process</h3> <p>In the process of performing a systematic review, there is a group of biases called significance‐chasing biases (<a href="./references#CD010340-bbs2-0098" title="IoannidisJP . Meta‐research: The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). This group includes publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<a href="./references#CD010340-bbs2-0098" title="IoannidisJP . Meta‐research: The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. This Cochrane review has a low risk of publication bias due to the thorough trial search process. Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to study publication bias, in that 'negative’ results remain unpublished (<a href="./references#CD010340-bbs2-0098" title="IoannidisJP . Meta‐research: The art of getting it wrong. Research Synthesis Methods2010;1(3‐4):169‐84. ">Ioannidis 2010</a>). This Cochrane review found that <a href="./references#CD010340-bbs2-0001" title="BrodskyRA , MuusP , DührsenU , HillA , BesslerM , CoutreS , et al. Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:3770. HillA , RotherRP , WangX , MorrisSM , Quinn‐SengerK , KellyR , et al. Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2010;149(3):414‐25. [PUBMED: 20230403] HillA , RotherRP , WangX , SapsfordRJ , CollinsonPO , GazeDC , et al. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis‐associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria. Blood2009;112:486. [CN‐00782913] HillA , SchubertJ , DuhrsenzU , YoungNS , ElebutezM , SzerJ , et al. TRIUMPH, a randomized placebo‐controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH. British Journal of Haematology2007;137(Suppl 1):33‐4. HillmenP , ElebuteM , KellyR , Urbano‐IspizuaA , HillA , RotherRP , et al. Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology2010;85(8):553‐9. [PUBMED: 20658586] HillmenP , MuusP , DuhrsenU , RisitanoAM , SchubertJ , LuzzattoL , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood2007;110(12):4123‐8. [PUBMED: 17702897] HillmenP , MuusP , RöthA , ElebuteMO , RisitanoAM , SchrezenmeierH , et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2013;162(1):62‐73. [PUBMED: 23617322] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria. Haematologica2006;91:0535. [CN‐00625348] HillmenP , YoungNS , SchubertJ , BrodskyRA , SocieG , MuusP , et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine2006;355(12):1233‐43. [PUBMED: 16990386] KellyR , ArnoldL , RichardsSJ , HillA , BomkenC , HanleyJ , et al. Successful pregnancy outcomes in paroxysmal nocturnal hemoglobinuria with long‐term eculizumab treatment. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:4576. RothA , KorperS , HochsmannB , Siegmund‐SchulzH , MurawskiN , SchubertJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anaemia in patients with paroxysmal nocturnal haemoglobinuria: phase III TRIUMPH‐study results. Onkologie2007; Vol. 30, issue Suppl 3:92. [CN‐00661421] SchubertJ , HillmenP , DührsenU , YoungNS , ElebuteM , SzerJ , et al. Treatment with the terminal complement inhibitor eculizumab improves anemia in patients with paroxysmal nocturnal hemoglobinuria: phase III Triumph study results. Blood (ASH Annual Meeting Abstracts). 2006; Vol. 108:124. SchubertJ , HillmenP , RothA , YoungNS , ElebuteM , SzerJ , et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology2008;142(2):263‐72. [PUBMED: 18503589] SocieG , MuusP , SchrezenmeierH , HöchsmannB , MaciejewskiJP , WeitzIC , et al. Terminal complement inhibitor eculizumab improves complement‐mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009; Vol. 114:4030. ">TRIUMPH 2006</a> has a high risk of selective outcome reporting because this trial did not report overall survival and other main clinical outcomes such any fatal or nonfatal thrombotic events, transformation to myelodysplastic syndrome and acute myelogenous leukemia, and development and recurrence of aplastic anemia on treatment. </p> </section> <section id="CD010340-sec-0088"> <h3 class="title" id="CD010340-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>There are no other systematic reviews for comparison with this Cochrane review. The AEGIS clinical trial, an open‐label, single‐arm, multicenter study in 29 Japanese patients who were 12 years of age or older with a diagnosis of PNH for at least six months, reported reduction in transfusion requirements, and reduction in fatigue (<a href="./references#CD010340-bbs2-0002" title="KanakuraY , OhyashikiK , ShichishimaT , OkamotoS , AndoK , NinomiyaH . Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: AEGIS phase II clinical study results. Blood (ASH Annual Meeting Abstracts). 2008; Vol. 112:3438. KanakuraY , OhyashikiK , ShichishimaT , OkamotoS , AndoK , NinomiyaH , et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. International Journal of Hematology2011;93(1):36‐46. [PUBMED: 21222185] ">AEGIS 2008</a>). However, this trial is limited by the methodology issue. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010340-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010340-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010340-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010340-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eculizumab versus placebo, Outcome 1 Health‐related quality of life and fatigue (Assessed by EORTC QLQ‐C30 instrument)." data-id="CD010340-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Eculizumab versus placebo, Outcome 1 Health‐related quality of life and fatigue (Assessed by EORTC QLQ‐C30 instrument). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#CD010340-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eculizumab versus placebo, Outcome 2 Fatigue (Assessed by FACIT‐Fatigue instrument)." data-id="CD010340-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Eculizumab versus placebo, Outcome 2 Fatigue (Assessed by FACIT‐Fatigue instrument). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#CD010340-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eculizumab versus placebo, Outcome 3 Serious adverse events." data-id="CD010340-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Eculizumab versus placebo, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#CD010340-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eculizumab versus placebo, Outcome 4 Adverse event (most frequents)." data-id="CD010340-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Eculizumab versus placebo, Outcome 4 Adverse event (most frequents).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#CD010340-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eculizumab versus placebo, Outcome 5 Transfusion independence." data-id="CD010340-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Eculizumab versus placebo, Outcome 5 Transfusion independence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#CD010340-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010340-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/urn:x-wiley:14651858:media:CD010340:CD010340-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_t/tCD010340-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eculizumab versus placebo, Outcome 6 Withdrawal for any reason." data-id="CD010340-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Eculizumab versus placebo, Outcome 6 Withdrawal for any reason.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#CD010340-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/media/CDSR/CD010340/image_n/nCD010340-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010340-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Eculizumab compared with placebo for paroxysmal nocturnal hemoglobinuria</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Eculizumab compared with placebo for paroxysmal nocturnal hemoglobinuria</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with paroxysmal nocturnal hemoglobinuria<br/> <b>Intervention:</b> eculizumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>1</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Eculizumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall survival</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured in the included study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> <br/> Follow‐up: at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No patients died during the execution of the included study. The small sample size of the included trial does not allow to make judgments about the quality of evidence </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome)<br/> Follow‐up: at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the health‐related quality of life score in the control group was<br/> <b>‐8.5</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the health‐related quality of life score in the intervention group was<br/> <b>19.4 higher</b> <br/> (8.25 to 30.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatigue</b> <br/> Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐Fatigue). Scale from: 0 to 52 (a higher score means a better outcome)<br/> Follow‐up: data at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the fatigue score in the control group was<br/> <b>‐4.0 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in the fatigue score in the intervention group was<br/> <b>10.4 higher</b> <br/> (9.97 to 10.83 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (serious and nonserious)</b> <br/> Medical Dictionary for Regulatory Activities (MedDRA)<br/> Follow‐up: data at 26 weeks of treatment<sup>2,9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>205 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> <br/> (31 to 280) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.45</b> <br/> (0.15 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion independence</b> <br/> Follow‐up: data at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>920 per 1000</b> <br/> (58 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 46.02</b> <br/> (2.88 to 735.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal for any reason</b> <br/> Follow‐up: data at 26 weeks of treatment<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> <br/> (11 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.20</b> <br/> (0.05 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Assumed risk is based on the risks for the control group in the included trial.<br/> <sup>2</sup> In the TRIUMPH trial patients received treatment for 26 weeks.<br/> <sup>3</sup> Limitations in design and execution: Outcome assessment was performed in an open fashion (for subjective outcomes), and attrition in placebo group due to the perceived a lack of efficacy could bias the reported estimates.<br/> <sup>4</sup> Imprecision: Low sample size (87 participants) resulting in confidence intervals suggesting moderate to important changes in quality of life.<br/> <sup>5</sup> Imprecision: Low rate of adverse events (13 in total) resulting in wide confidence intervals; quality of evidence lowered by two levels due to very serious imprecision.<br/> <sup>6</sup> Assuming a control group risk of 2% (equivalent to one event in this group).<br/> <sup>7</sup> Imprecision: Low rate of adverse events (22 in total, none of them in control group) resulting in wide confidence intervals.<br/> <sup>8</sup> Imprecision: Low rate of adverse events (12 in total) resulting in wide confidence intervals.<br/> <sup>9</sup> Quality of evidence rated and effect estimates obtained for serious adverse effects. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Eculizumab compared with placebo for paroxysmal nocturnal hemoglobinuria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/full#CD010340-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010340-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Eculizumab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Health‐related quality of life and fatigue (Assessed by EORTC QLQ‐C30 instrument) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Global health status scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.4 [8.25, 30.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatigue (Assessed by FACIT‐Fatigue instrument) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.4 [9.97, 10.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.4 [9.97, 10.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Overall serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.15, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Exacerbation of PNH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Renal colic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.13, 73.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Lumbar‐ or sacral‐disk prolapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.13, 73.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 α‐Hemolytic streptococcal bacteremia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.13, 73.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Central‐line and urinary tract infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Probable viral infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Cellulitis, folliculitis, and neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Anemia and pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse event (most frequents) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.90, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.56, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.24, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.66, 6.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.49, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Transfusion independence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>46.02 [2.88, 735.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawal for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.05, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Eculizumab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010340.pub2/references#CD010340-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010340.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010340-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010340-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010340-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010340-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010340\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010340\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010340\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010340\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010340\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010340.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010340.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010340.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010340.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010340.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726358285"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010340.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726358289"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010340.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e91b44de39368',t:'MTc0MDcyNjM1OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 